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CHAPTER I 
 
DISSERTATION OVERVIEW 
 
1.1 INTRODUCTION & RESEARCH QUESTION 
It is well-known that the majority of engineering, information technology, and 
construction projects either fail outright, or only achieve their goals at a significantly 
higher cost in terms of time and resources.1, 2 Interestingly, there has been little 
investigation of the success or failure rates of health-related projects, most notably in the 
area of clinical trials.   A clinical trial is a research study that tests how well new medical 
approaches work in people.3 Clinical trials involving therapeutic drug agents proceed 
through a series of research experiments, or phases (I, II, and III), to gain scientifically 
supported insight prior to Food and Drug Administration (FDA) approval for such agents 
to be utilized by the general public.4 Each clinical trial is regarded as a project in itself; 
for example, a phase III clinical trial in oncology requires approximately 784 calendar 
days to develop a single phase III clinical trial across 370 distinct processing steps 
involving more than 30 participants.5, 6 If one considers the development of a drug as a 
“project”, a potential therapeutic agent going through the series of phase I, II, and III 
trials translates to approximately $802 million (2003 USD).7, 8 
The purpose of my research is to discover if there are early indicators of the eventual 
success of a clinical trial. Success, in the case of a clinical trial, will be measured from an 
operations perspective, i.e., a trial will be considered successful if it enrolls, or accrues, a 
sufficient number of patients such that a scientifically meaningful conclusion can be 
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drawn. This number of patients is typically identified in the trail design, or protocol, itself 
and is referred to as the accrual goal.  Inversely, a failure of a clinical trial is the 
discontinuation of a trial before it achieves the minimum specified accrual goal.  
Recent research has discovered that less than one in five cancer clinical trials 
conducted results in publication in peer-review journals, hence a large number of clinical 
trials are conducted without achieving their intended objective.9 While the selective 
publication of clinical trials with negative results affects publication acceptance, a greater 
and often overlooked impact lies within the inability to achieve the adequate number of 
enrollments to demonstrate the scientific hypothesis.10 In one setting, that of 
Comprehensive Cancer Centers, a sample from four major such institutions showed that 
greater than twenty-three (23%) of clinical trials selected to enter the portfolio (i.e. 
opened for accrual) did not even achieve the minimum patient accrual, hence no valid 
scientific outcomes could be observed.11, 12 Obviously, there are substantial barriers to 
achieving clinical trial success, thus preventing the advancement of both scientific 
knowledge and the improvement of clinical practice. 
Two primary aspects that may influence success of a clinical trial that will be 
investigated in this research are 1) factors that are related to the design and development 
stage of the trial and 2) factors that are observed once a trial is launched, or opened for 
patient accrual.   
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Formally, the research questions posed for my dissertation are (Figure 1-1): 
1. Does development time of a cancer clinical trial impact the likelihood of 
achieving success, i.e., achieving the minimum accrual goal? (Chapter 2) 
2. Are there early indicators of a cancer clinical trial, once it is open to 
accrual that can be used to help predict the eventual success? (Chapter 3) 
3. What characteristics of the design of the clinical trial impact the 
development time of a cancer clinical trial? (Chapter 4) 
 
The types of clinical trials investigated are oncology clinical trials supported 
through the National Cancer Institute (NCI). The primary focus of the research is to be 
able to assist the decision-makers within the NCI and clinical trials offices of academic 
and medical institutions during the development process in order to improve the 
likelihood that the trial will be successful with respect to accruals. Also, my research will 
provide guidance to such decision-makers during the conduct of a trial as to the 
likelihood of a trial successfully achieving its accrual goal once it has been activated or 
opened. 
1.2 THEORETICAL FRAMEWORK AND LITERATURE REVIEW 
1.2.1 Clinical Trials as a Healthcare Project  
The development of a clinical trial is akin to the new product development 
process. A project is defined as a “complex effort made up of interrelated tasks, 
performed by various organizations, with a defined set of objectives, schedules, and 
budgets” 13.  For the purpose of my research, a project is a clinical trial.  A clinical trial is 
a project that focuses on research to test how well new medical approaches work in 
people.3 The development of a clinical trial is composed of various components such as 
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the protocol, forms, contracts and grants negotiation, as well as the many review 
functions.  Each of these components is developed by specialized participants in the 
development process, such as physicians, research nurses, protocol editors, regulatory 
specialists, lawyers, and financial analysts.  Each of these participants must coordinate 
with each other during the development processes to form the final resulting product of a 
clinical trial.   
The intersection between portfolio planning through project selection and its 
application to healthcare is a ripe opportunity to improve the implementation of cancer 
clinical practices.  Dimasi et al.8 have documented the enormous costs and time 
associated with the new drug discovery process including the conduct of clinical trials. 
Previous research to uncover more descriptive detail of the clinical research process by 
Dilts et al6, 14 has found that a significant amount of time and effort required to conduct a 
clinical trial is consumed in clinical trial setup from concept inception to study activation. 
Yet much of the research conducted on the productivity of clinical research is centered on 
the operations of post-activated clinical trials in the form of participation of patients in 
the available clinical trials.15-19 Little research is available on the decisions and processes 
required to design and activate a study or on how factors known at concept design may 
predict eventual accrual performance. 6   
Noting the lack of published research in the area of clinical trial pre-activation 
activities (including clinical trial selection), a number of initiatives have been 
implemented which focus on improving the setup time by means of prioritizing clinical 
trials in order to accrue more patients to meaningful studies.20, 21 These initiatives could 
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benefit from research that demonstrates the impact of the clinical trial selection decision 
on the overall performance of the portfolio. 
1.2.2 Product Development Time vs. Clinical Trial Development Time 
Fast cycle product development, or time-to-market, has been identified as a 
competitive advantage of a firm.22, 23 For example, Japanese automobile manufactures 
were able to develop new models of vehicles and integrate innovations faster in order to 
meet the demands of the market.24-26 Much like the new product development cycle, 
delays in the development cycle can drastically affect the resulting outcome of the 
performance of the clinical trial.  In the automotive industry, it has been estimated that 
each day of delay in introducing a new car costs the organization about $1M loss in 
profit.27 This is analogous to the pharmaceutical industry where each day of delay to 
market a new pharmaceutical product costs the manufacture about $1.3M.28 
While the development time for other new-to-the-world products have decreased 
from 41.7 months to 24 months from 1995 to 2004 (a decrease of 42%), the time to 
develop a new drug has increased from 56.4 to 144months (increase of 155%) during the 
same time frame.29, 30 Along with this increase in time are escalating costs for drug 
development, with costs reaching over $800 million per drug. Thus, pharmaceutical firms 
must rely on external partners, suppliers, and government agencies to aid in new drug 
development.8, 29  
Comparing the success of a product or project and the outcomes of a clinical trial 
cannot be measured utilizing the same metrics.  Specifically, new product success can be 
measured by profit or other monetary measurement while clinical trial success is 
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measured on scientific merit of the study outcome.  While scientific merit is difficult to 
measure in a fungible manner, success of a clinical trial can be measured by whether or 
not the trial enrolled sufficient accruals in order to statistical support the trial’s scientific 
objectives.  Insight to this research will allow the comparison of the clinical trial 
development process to other new product or project development.   
1.2.3 Measurement of Project Success 
A substantial amount of literature has focused on the question of which projects 
an organization should pursue.  One perspective into this decision is the assessment of 
individual project characteristics as they relate to project outcome (either success or 
failure).  There have been several reviews on this subject that can be found in 
Balachandra and Friar2, Dilts and Pence1, Lilien and Yoon and Linton et al31.  Research 
has focused on understanding project characteristics in order to improve the number of 
successful projects or to avoid project failure.  Identifying the evaluative factors that lead 
to overall project success have been shown to yield an overall performance improvement 
in the project selection into the portfolio compared to actual portfolio performance.32, 33 
The justification behind research supporting the identification of characteristics of a study 
characteristics that correlate with outcomes is that decision makers make costly, ill-
informed project selection decisions that could have been avoided with clearly defined 
up-front evaluative criteria.34, 35 
Unfortunately, while there is an acknowledgement of the importance of clearly 
defining project characteristics that lead to success, a lack of convergence of project 
characteristics that correlate to outcome has resulted in little managerial impact and 
improvement to project selection decisions.2, 22, 36 Balachandra and Friar have argued that 
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the lack of agreement among the identified project characteristics is a result of the 
uniqueness of characteristics dependent upon the type of project. 2 On the other hand, 
Krishnan and Ulrich37 argue that past research has shown that there are only a handful of 
research studies supported by empirical evidence, with the majority of research founded 
on the opinions of surveyed participants. Table 1-1 presents a summary of the past 
studies and categorizes each by the study setting and the methodology used.  The 
summary of literature supports the observation that there is little research that utilizes 
objective data to support the research findings.  Furthermore, there is a lack of project 
success research that has incorporated the research of predicting project success in a 
health-care setting.  My research will utilize objective data in a health-care setting, 
specifically in the development of oncology clinical trials sponsored by the NCI, to aid in 
predicting the success of such projects.  
Research to understand how various project characteristics correlate to project 
success in a healthcare setting can provide insight into which factors are used to predict 
success.  Furthermore, including objective data in the research will allow the comparison 
between quantitative factors that correlate to success. 
1.3 RESEARCH SETTING 
The Cancer Therapy Evaluation Program (CTEP) is involved in planning, 
reviewing, and coordinating clinical trials that are supported by the National Cancer 
Institute (NCI). CTEP is involved with investigational anticancer agents, novel 
therapeutic approaches to cancer treatment that are financially supported through the 
NCI. CTEP evaluates approximately 900 of the 1500 NCI-sponsored trials annually.38 
Each of the trials evaluated and approved by CTEP is supported by grants and 
  8 
cooperative agreements from the NCI awarded to scientific institutions and individuals, 
and are conducted, at a minimum, by the faculty members and practitioners at those 
institutions who initiated the study idea.  CTEP enrolls approximately 25,000 patients 
annually and conducts clinical trials at 1,958 institutions encompassing close to 10,000 
investigators.  Institutions that conduct CTEP-sponsored clinical trials included Cancer 
Centers, Comprehensive Cancer Centers, Cooperative Groups, Consortiums, US 
Government Agencies (such as NIH and NCI), and some international studies. Each of 
these intuitions is defined in Table 1-4.  
A primary function of CTEP is to monitor and track the progress of clinical trials 
that are going through development, accruing patients, and are complete.  This task is 
conducted by the Protocol Information Office (PIO) by means of supporting databases of 
past, ongoing, and future studies.  
1.2.4 Sources of Data 
Retrospective data for this research are gathered from the CTEP-PIO database, for 
clinical trial data between January 1, 2000 and December 31, 2007.  A total of 5845 
clinical trials are documented within this time frame which were either in development, 
accruing patients, completed, or had been disapproved.  While each analysis in my 
dissertation utilizes the same database, samples drawn from this database are dependent 
upon the research question for that chapter. For example, to investigate the relationship 
between development time and accrual success in Chapter 2, the sample contains only 
trials that have both complete development time and have been closed to accrual. 
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Understanding early accrual indicators towards eventual accrual success will 
utilize trials that have been opened to accrual and completely closed to accrual in the 
sample collection period.  Furthermore, only trials that have complete accrual 
information, that is, trials that have monthly records of accrual enrollment by patient 
through the Clinical Data Update System (CDUS) or Clinical Trial Management System 
(CTMS) are included in the analysis in Chapter 3. 
Trials that have complete development time information are used to identifying 
characteristics that are related to development time as described in Chapter 4.  Thus, trials 
included in this analysis must have complete trial characteristic information. 
1.2.5 Measuring Trial Success 
Project success is studied frequently, but the basic definition is rarely agreed 
upon. 39 Because the definition of success is attributed to the decision maker’s 
perspective, past literature has simplified the definition of project success by equating it 
to meeting objectives of budget and schedule while achieving an acceptable level of 
performance.40-42 A measure of success is then compiled based on these three factors 
using a scoring method such as the averaging of the three variables, weighted average, or 
processes such as analytical hierarchy process.43-45 This issue tends to complicate the 
overall finding of the research and opens up the final outcomes to criticism.  
For the purpose of my research, success is based on a single measure: trials 
achieving stated accrual objective.  This greatly simplifies the ambiguity regarding the 
definition of a successful project.  Clinical trials, like many scientific research endeavors, 
require a sufficient sample size (i.e., accruals) to arrive at statistically sound conclusions.  
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Once the sample size of the clinical trial is achieved, the primary questions defined in the 
clinical trial idea can be answered.  Achieving sufficient accruals on a clinical trial is the 
minimum required objective that is necessary to achieve all other study objectives 
including scientific discovery, publication within academic journals, and development of 
new treatment options.  It is important to note that success is not defined in terms of 
accepting or rejecting the stated scientific hypotheses in the trial; rather it is acquiring 
sufficient sample sizes (i.e., accruals) in order to test the trial hypotheses. 
Based on our previous study, we have found a precipitous drop off of phase III 
cancer trials that achieve accrual goals of 80% of the maximum accrual goal and those 
that do not (Figures 1-2).  Rather than utilizing the maximum accrual goal, I utilize a 
more liberal estimate of trial success by basing it on those trials achieving 100% of 
minimum accrual goal.  I acknowledge that trial findings may be published without 
achieving adequate number of enrollments to demonstrate the scientific hypothesis, but it 
is noted that this is often observed only in trials with negative results.10 
Because there is a clear distinction between trials that achieve stated accrual goals 
and those that do not, I use this dichotomous variable as the definition of clinical trial 
success throughout the research. 
1.4 RESEARCH PROPOSITIONS 
Three main propositions are addressed in this research. The propositions are 
interrelated and will build upon prior findings.  A model illustrating the interaction of the 
propositions is shown in Figure 1-1.   
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1.4.1 Relationship Between Clinical Trial Development Time and Accrual Success 
Most efforts to reduce barriers to patient accruals have been concentrated on post-
activation efforts, that is, after a trial is open for patient enrollment or accrual.46, 47  With 
recent findings that a large portion of time “conducting” a clinical trial is concentrated in 
the development and preparation, understanding of barriers during the pre-activation 
efforts must be uncovered.48 A phase III clinical trial can take an estimated 26 months to 
develop requiring intricate collaboration among a diverse set of organizations.5, 49-51  
More importantly, understanding how the time required to develop a clinical trial impacts 
the likelihood of achieving accrual success will allow the identification of pre-activation 
barriers that significantly affect post-activation clinical trial performance.  The 
proposition is addressed in chapter 2 and clarified in greater detail. 
Proposition 1a:  An increase in the time required to develop a 
clinical trial will have a negative impact on the likelihood of 
accrual success. 
  
1.4.2 Early Predictors in Accrual and Accrual Success 
The projected accrual rates of those clinical trials conducted in the past have been 
found to be over-estimated compared with actual accrual rates, thus causing trials to be 
open to accrual longer than planned.52 Uncovering the relationship between accrual 
performance at specific milestones, such as first patient enrollment and expected time to 
achieve accrual goal, with the eventual accrual success of the trial will allow for a greater 
understanding on the factors that help clinical trials success overall.  Specifically, early 
indicators of accrual success can support early decisions to manage clinical trials during 
the accrual period.  These results may provide the ability to intervene on trials with low 
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accrual and improve the likelihood of them achieving the scientific objective or, 
conversely, stopping resources from being invested in prolonging trials that have a low 
likelihood of accrual success.  Regardless of decision, the ability to utilize predictors of 
accrual success in the conduct of the clinical trial will allow subjects (i.e., patients) 
enrolled on trials to have the greatest chance to contribute to the state of medical 
knowledge and improve the efficiency of resources and effort in conducting clinical 
trials. 
Proposition 2a:  Clinical trials with faster time to first enrollment 
will have a positive impact on the likelihood of accrual success. 
 
 With a large number of clinical trials underestimating the time to achieve a 
specific accrual goal, an analysis of the actual accrual goal can be conducted relative to 
the expected time to achieve the accrual goal.  Based on this analysis at the specified 
milestone, early assessment of the clinical trial is conducted in Chapter 3.   
Proposition 2b:  The accrual performance at the expected time to 
achieve the accrual goal is correlated to the eventual accrual 
success. 
 
 Cancer incidence, or the occurrence of specific types of cancer in the population, 
as well as cancer mortality rate, or occurrence of death by a specific type of cancer in the 
population, may have a moderating affect on the relationship between time-to-first 
enrollment and accrual success.  Therefore I test this relationship and control the 
outcomes of the analysis for this relationship.  While approximately 2 – 7 % of the 
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population with cancer enroll on clinical trials, specific types of cancer have a higher 
incidence and therefore a greater number of patients available to enroll on such clinical 
trials.  The cancer mortality rate may impact the accrual performances due to the severity 
of the disease and the demand to find additional treatment options. 
Proposition 2c:  Clinical trials directed towards cancers of 
greater incidences will have a shorter time-to-first enrollment 
then on those with lower incidences. 
Proposition 2d:  Clinical trials directed towards cancers of 
greater mortality will have a shorter time-to-first enrollment on 
those with lower mortality. 
 
1.4.3 Characteristics Impacting Development Time 
Understanding the clinical trial characteristics that are attributed to development 
times is important in order to be able to effectively manage clinical trial development.  
From the data of the available clinical trials recorded through the CTEP-PIO database, 
over 30 quantifiable characteristics have been recorded in either the NCI-concept sheets 
or NCI-protocol sheets. 
From the perspective of the principal investigator who is designing the clinical 
trial, it is important to have a relative understanding the length of a specific clinical trial 
development and what the likelihood of completing accruals to the trial are. This is the 
focus of Chapter 4. 
Proposition 3a:  General clinical trial characteristics can be 
utilized as indicators to estimate clinical trial development times. 
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1.5 ORGANIZATION OF DISSERTATION 
The following chapters address the three sets of propositions in three chapters that 
are formatted based on the targeted peer-review journals.  The findings related to 
proposition 1 are found in chapter II:  “A Sense of Urgency – Evaluating the Link 
between Clinical Trial Development Time and Accrual Performance of CTEP-Sponsored 
Studies.”  Research findings related to proposition 2 are found in chapter III titled: 
“Predicting Accrual Success – Accrual performance of NCI CTEP-Sponsored Clinical 
Trials”.  Proposition 3 research and findings are found in chapter IV titled: “Impact of 
Clinical Trial Characteristics on Development Time of NCI CTEP-sponsored Clinical 
Trials.”  Finally, summary of the findings and proposed future studies are found in 
chapter V and VI. 
References that are specific to the design and development of oncology clinical 
trials through CTEP are used throughout this dissertation.  The definition of a clinical 
trial as well as the progressive phases that must be conducted prior to approving a 
therapeutic agent for market are outlined in Table 1-2.  The various organizations and the 
scope of the main participants that are involved in conducting a clinical trial are defined 
in Table 1-3.  Formal definitions from the National Cancer Institute Dictionary of Cancer 
Terms regarding the process required to develop a oncology clinical including the 
necessary protocol-specific items that need to be completed as well as the clinical trial 
development and accrual milestones are also provide in Table 1-4.3
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FIGURE 1-1:  RESEARCH MODEL 
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*Note: Accrual goal based on maximum projected accrual goal 
FIGURE 1-2: PRELIMINARY DATA ON PHASE III THERAPEUTIC CLINICAL TRIAL ACCRUAL PERFORMANCE BASED ON MAXIMUM 
ACCRUAL PERFORMANCE 
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CHAPTER II 
 
A SENSE OF URGENCY:  EVALUATING THE LINK BETWEEN CLINICAL 
TRIAL DEVELOPMENT TIME AND THE ACCRUAL PERFORMANCE OF 
CTEP-SPONSORED STUDIES 
2.1   PREFACE AND RESEARCH MODEL 
 Little research has looked at barriers to clinical trials during the development 
period; No research has investigated the impact of development time of a clinical trial on 
the success of a clinical trial.  Research in chapter delves into the relationship between of 
these two factors to understand whether studies with faster development time do in fact 
have a greater likelihood of success.  We utilize a measure of clinical trial success based 
upon the achievement of projected accrual goals, as this is the minimum requirement 
necessary to statistically support the intended scientific objective.   
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2.2 ABSTRACT 
Background  Post-activation barriers to oncology clinical trial accruals are well 
documented; however, potential barriers prior to trial opening are not.  We investigate 
one such barrier: trial development time. 
Methods  National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) 
sponsored trials for all therapeutic, non-pediatric phase I, I/II, II, and III studies activated 
in an eight year period (2000-2007) were investigated (n=553).  Successful trials were 
those achieving 100% of minimum accrual goal.  Time to open a study was the calendar 
time from initial CTEP submission to trial activation.  Multivariable logistic regression 
analysis was used to calculate unadjusted and adjusted odds ratios, controlling for study 
phase and size of expected accruals. 
Results  40.0 percent (n=221) of CTEP-approved oncology trials failed to achieve 
minimum accrual goals, with 49.2 percent (n=30) of phase III trials failing to achieve at 
least 25 percent of accrual goals.  A total of 8,723 patients (17.0% of accruals) accrued to 
those studies that were unable to achieve the projected minimum accrual goal.  Trials 
requiring 9-12 months development were significantly more likely to achieve accrual 
goals (odds ratio, 1.94; 95% CI, 1.06 to 3.52, P=0.031) than trials requiring the median 
time (15-18 months); trials that exceeded 27 months of development time were 
significantly less likely of achieving accrual goals (odds ratio, 0.14; 95% CI, 0.04 to 0.54, 
P=0.004).   
Conclusions  A large percentage of oncology clinical trials do not achieve minimum 
projected accruals.  Trial development time appears to be one important predictor of the 
likelihood of successfully achieving the minimum accrual goals.
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2.3  INTRODUCTION 
 In the United States, it is estimated that 1.4 million individuals will be diagnosed 
with cancer, and over half a million will die each year.  Advances in therapeutic 
treatments have improved the 5-year survival rates over the past four decades,1 yet 
cancer continues to be the second leading cause of death in Americans, resulting in more 
deaths than the next five causes combined.2   New and innovative therapeutic approaches 
to improve the standard of care of cancer patients must be developed and then confirmed 
through a series of clinical trial phases to ensure both efficacy and safety.3  Phases I-III 
trials require sufficient patient enrollment so that the efficacy of the therapeutic agent(s) 
under investigation can be measured with a proper degree of statistical certainty.  
 Unfortunately, with only 2-7% of the adult cancer population participating in 
clinical trials, obtaining sufficient accrual is a known barrier to successful completion of 
clinical trials.
4, 5
 Furthermore, it has been shown that the lack of appropriate trials 
represents a significant barrier to accruing oncology patients.
6
 Hence, there should be a 
sense of urgency to develop properly safeguarded oncology trials such that treatments 
discovered at the bench can be translated effectively and rapidly into improved standard 
of care. 
Understanding the reasons behind low accruing clinical trials is important.  
However, most of the efforts to reduce barriers to patient accruals have been concentrated 
on post-activation efforts, that is, after a trial is open for patient enrollment or accrual.
7, 8
 
It is our contention that there are factors involved during trial development that 
significantly impact accrual performance.  We postulate that the calendar time required to 
transit from letter of intent (LOI) or concept through protocol development to final trial 
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activation is inversely related to successful accrual goal achievement.  Research has 
shown that the time to develop a phase III oncology trial requires nearly 26 months with 
intricate collaboration among a diverse set of organizations. 
9
 While there are a host of 
other causes that may be attributed to low accruing clinical trials, development time has 
been shown to be a well-established and critical factor in the success of a new product 
across a host of other applications.
10
 
To investigate the effect of trial development time on patient accruals to oncology 
trials, a retrospective evaluation was conducted on trial sponsored by the National Cancer 
Institute (NCI) Cancer Therapy Evaluation Program (CTEP).  CTEP evaluates 
approximately 900 out of the 1500 NCI-sponsored studies annually.
11
 Each of the study 
evaluated by CTEP is supported by grants and cooperative agreements from the NCI 
awarded to scientific institutions and individuals and are conducted by the faculty 
members and practitioners at those institutions who initiated the study idea.  This article 
uncovers the critical, yet often overlooked, barrier of lengthy trial development time as a 
major factor negatively impacting accrual performance in phases I-III oncology trials.   
2.4 METHODS 
All therapeutic, non-pediatric, phase I, I/II, II, and III oncology trials evaluated by 
CTEP that began trial development, opened to patient accrual, and subsequently closed to 
accruals between January 1, 2000 and December 31, 2007 in the United States were 
eligible.  Data were supplied by the CTEP Protocol and Information Office (PIO), which 
maintains a tracking database of trial activities from concept submission to trial 
activation.
12
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The independent variable, development time, was the difference in calendar days 
between the date of initial CTEP receipt of LOI or concept and the date the trial was 
opened for accrual.  For simplicity, calendar days were converted into months by 
dividing the total days by 30.33.  When an activation time was missing (n=14, 2.5%), the 
date at which the institution activated or opened the study was used.  It is important to 
note that this definition of development time does not include the days required to 
prepare the trial idea into a formal submission to CTEP.  Previous studies of phase III 
trials have shown that this initial time can consume between 1 and 10 calendar months.
9
 
The dependent variable, accrual-to-goal percent, was calculated using projected 
minimum accrual goal and actual final trial accrual.  This provides a liberal estimate of 
trial success because it defines the minimum trial sample size needed to achieve desired 
scientific endpoint.  If minimum patient accrual information was not available (n=5, 
1.0%) the maximum patient accrual goal was used. 
Final patient accrual was obtained from the CTEP-PIO database, with input from 
the Clinical Data Update System and the Clinical Trials Monitoring Service.  Only trials 
permanently closed to accrual were analyzed, i.e., those temporarily closed to patient 
accrual and/or treatments for any other reason were excluded. 
Accrual-to-goal percent was computed by dividing the actual trial final accrual by 
the projected minimum study accrual goal.  Success was defined as a trial that achieved 
100% of accrual-to-goal percent. 
Clinical trials were divided among 6 groups based on accrual-to-goal percentages 
(0%, 1-24%, 25-49%, 50-74%, 75-99%, and 100%).  Data were also analyzed and 
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segmented by trial development time at 3-month intervals to observe the impact of trial 
development time on achievement of minimum accrual goal in terms of odds ratios.   
2.5  STATISTICAL ANALYSIS 
 Continuous variables were summarized by calculating medians and interquartile 
ranges (IQRs).  A maximum 2-tailed alpha of 0.05 was maintained for determining 
statistical significance.  Comparisons among trial types (i.e. phases I, I/II, II, III) were 
conducted using the Kruskal-Wallis test.  Post-hoc comparisons of statistically significant 
overall tests used Mann-Whitney tests with a Bonferroni-adjusted alpha level of 0.008.  
Categorical and ordinal groups were summarized using univariate and cross-tabulated 
frequency distributions.  Unadjusted and adjusted odds ratios, along with their respective 
95% confidence intervals, were obtained using multivariable logistic regression analysis.  
Polynomial regression terms were used for overall patterns of trend.  These results were 
compared with results using incident-rates from Poisson regressions.  Statistical analyses 
were performed in either SPSS (version 15.0, descriptive and logistic regression) or Stata 
(version 10, logistic and Poisson regression). 
2.6  RESULTS 
A total of 553 CTEP-sponsored phase I, I/II, II, and III therapeutic, non-pediatric 
oncology trials that were initiated and closed to patient enrollment within the study 
period were eligible.  Table 2-1 summarizes the development time and minimal accrual 
characteristics by phase of trial.  Phase II trials accounted for the majority (58.6%, 
n=324); phase I trials composed 22.2% (n=123), followed by phase III (11.0%, n=61) and 
phase I/II (8.1%, n=45).  Trials with incomplete timing data were excluded.  No 
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statistically significant differences in accrual achievement between included and 
excluded studies were observed (P<0.001).   
Overall median development time from initial CTEP submission to study 
activation for all types of trials was 15.0 months (interquartile range (IQR): 11.6– 19.4).  
Phase III trials had statistically longer development time than other types (P<0.008) with 
a median development time of 18.3 months (IQR: 14.2– 26.0).  None of the differences in 
development time between the other types of trials were statistically significant. 
Median minimum projected accrual goal for all types of trials was 22 subjects 
(IQR: 15-42)(Table 2-1).  There were significant differences in projected minimum 
accrual goals between phase I trials compared with phase I/II, phase II, and phase III 
trials (P<0.008). Additionally, phase III trials had significantly greater projected 
minimum patient accruals when compared with trials of all other phases (P<0.008). 
As shown in Table 2-1, 40.0% (n=221) of all trials did not achieve 100% of the 
projected minimum accrual goal.  However, performance of the phase III trials was 
statistically significantly lower than that of the other types of trials, with 63.9% (n=39) 
failing to achieve this standard of performance (P<0.001).  Particularly problematic in 
phase III studies, a large number of studies (n=30, 49.2%) failed to achieve 25% of their 
respective projected minimum accrual goals. 
A total of 51197 individuals accrued to the oncology trials in the sample.   The 
majority were enrolled in phase III trials (n=34361, 67.1%), followed by phase II 
(n=11718, 22.9%), phase I (n=3168, 6.2%), and phase I/II (n=1950, 3.8%).  When 
comparing the proportion of patients enrolled on trials based on the achievement of the 
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projected minimum accrual, a total of 8723 participants (17.0%, min=16.2% phase I, 
max=18.1% phase II) were enrolled on clinical trials that closed with underperforming 
final accruals (Figure 2-1). 
Visual inspection and statistical tests of the relationship between development 
time and probability of meeting minimum accrual goals indicated a statistically 
significant curvilinear component to the relationship (P=0.019 for the quadratic term) 
(Figure 2-2).  The shape of this relationship held when adjusted for the size of the trials 
based on the projected minimum accrual (P=0.020 for the quadratic term).  The results 
were very similar to those found using Poisson regression (P=0.033).   
For ease of interpretation, development time was collapsed into 3-month time 
intervals.  The rates for achieving minimum accrual goals tended to be highest within 3-6 
months of the overall median development time (15-18 months), slightly higher at briefer 
times for phase I, I/II, and II trials.  Rates of success decreased substantially as trial 
development time increased. Table 2-2 summarizes the likelihoods of achieving 
minimum accrual goals as the development time varied from the overall median 
development time.   
Relative to trials with a median development time of 15-18 months, trials taking 
9-12 months were statistical significant and more likely to achieve the minimum accrual 
goals compared to the remaining trials (OR=1.94; 95% CI, 1.24-4.57; CI=1.06-3.52; 
P=0.031).  On the other hand, trials requiring 27-30 months or >30 months in 
development time were statistically significant and less likely to achieve projected 
minimum accrual goals than those studies taking the overall median development time 
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(OR 27-30 months: 0.14, 95% CI, 0.04 – 0.54, P=0.004; OR >30 months: 0.17, 95% CI, 
0.07 – 0.41, P<0.001).  Studies with development times between 18-27 months had a 
proportionally decreasing likelihood of achieving minimum accrual goals, but the odds 
ratio was not significant (Table 2-2). 
Given the previously established differences in development time among the 
types of trial, the likelihood values adjusted for type of trial are also summarized.  
Additionally, raw projected minimum accrual numbers tend to be larger with phase III 
trials and given that those numbers provide a continuous (and thus more powerful) 
explanatory variable for whether or not accrual goals were met, thus the development 
time likelihood values adjusted for raw accrual projections are also displayed.  Odds 
ratios adjusted for raw projected accrual numbers or adjusted for the effect of phase III 
trials resulted in similar findings when compared to the unadjusted values.  
2.7  DISCUSSION 
This study provides an in-depth analysis of the development time of CTEP-
sponsored oncology clinical trials as it impacts study accrual performance during an 
eight-year period.  The findings demonstrate that the time to bring forth an idea from 
concept to study activation has a significant inverse relationship to accrual performance.   
The implications of identifying the correlation between development time and 
accrual performance are multiple.  First, trials have a limited capacity to derive any 
scientific findings without the adequate accruals necessary for statistical support.  
Additionally, the scarce resource of patients is being underutilized if patients volunteer 
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for a study that never achieves its minimum accrual goal.
†
  Data from this research show 
that approximately two of every five trials will fail to achieve sufficient accruals.  For 
phase III trials, the rate increases to three failures out of every five trials conducted, 
where nearly one in every two fails to achieve at least 25% of stated minimum accrual 
goals.  Along the same lines, 16-18% of participants were enrolled on a clinical trial that 
did not achieve minimum requirements in patient accruals.  If we assume that minimum 
sample size goals were developed using statistical power analysis, failure to achieve such 
goals results in the limited ability to derive statistically valid conclusions, and therefore 
result in a less significant advancement of science than originally intended.   
Unnecessary delays during the time required to develop a clinical trials can cause 
adverse implications in the likelihood of achieving the necessary accruals. The field of 
oncology clinical research evolves quickly which may cause interest in the original 
research question to wane.
13
 Alternatively, long development times as well as poor 
accruals may be due to the lack of interest in the clinical trial from the origination of the 
idea.  Regardless, pursuing clinical trials with a reduced likelihood of achieving accrual 
success limits the opportunity to conduct other clinical trials. 
In an era of clinical research where resources limit the number of trials that can be 
pursued, as well as the limited availability of individuals willing to participate in clinical 
trials, it is essential to identify potential causes of low accrual likelihood before allocating 
significant resources to develop such trials.  The retrospective analyses of phase I, I/II, II, 
and III trials suggest that there are opportunities to improve the number of successfully 
                                                
†
 We acknowledge that many clinical trials closed due to adverse events both related to the clinical trial itself as well as derived from 
other similar study.  Unfortunately we do not have the rational for study closing for the sample.   
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accruing trials.  In particular, phase III clinical trial development times should be 
improved not only because of the potential importance of their findings on current 
standard of care, but also because such trials are most resource-consuming in terms of 
time, effort, and patient accruals.   
Development time required for a trial is complicated by the many facets of 
scientific study design within the constraints of regulatory, ethical, and operational 
requirements.
14
 Research delays during the development of a clinical trial are often 
attributed to the improvement of overall scientific merit or to ensure safety of the 
potential participants.  However, opportunities to improve the development time arise 
when considering the number of non-value added (NVA) steps in the process flow, and 
the number of multiple, redundant, and overlapping steps that are involved in the opening 
of clinical trials. 
9, 15
 Findings from this research point to the fact that decisions that delay 
the deployment of clinical trials beyond the scope of scientific relevancy or ethical issues 
have negative repercussions on the likelihood of successful completion of the trial.  Such 
issues must be acknowledged when considering modifying a trial to add an additional 
study arm, an additional correlative, or otherwise “tinkering” with a trial. 
Finally, why is longer development time of interest beyond its ability to decreased 
likelihood of successful accruals? There are two other reasons: 1) patients will gain 
access to new therapies later (or not at all) than they otherwise would and 2) longer 
development times creates reduced innovation incentives as researchers concentrate on 
completing studies that have lower minimum patient accrual goals, which may result in 
fewer new therapies being developed.  Indeed, in the data used in this analysis, Phase III 
studies accounted for only 11% of all studies.  Academic researchers, who may be 
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struggling for tenure, are caught between Scylla and Charybdis
‡
:  remain close to the lab 
and attempt only studies requiring minimal accrual goals or attempt a clinically 
significant translational trial but with the knowledge that a) there is a limited chance of 
achieving even minimum accrual goals due to circumstances beyond their control, and b) 
without achieving such goals, research will not be published, the state of knowledge will 
not be advanced, and the likelihood of tenure diminished.  What should a rational 
untenured research decide?  Clearly, this is not a choice that any institution wishes for its 
best and brightest oncology researchers to have to make.  It is imperative that the systems 
and processes for clinical trial development be created to foster better and faster clinical 
trial development, with a minimum of administrative barriers. 
A limitation of this analysis is that only the development time variable has been 
analyzed with regard to successful accrual.  While there are hosts of other reasons for low 
accruals, this research has demonstrated that development time should be included in any 
investigation of low accrual causes as an important “barrier” to accrual.  Continued 
research to uncover additional barriers within pre-activation efforts is imperative in order 
to foster the rapid access of clinical trials to patients and improve the likelihood of 
achieving the desired clinical trial objective. 
 
 
 
                                                
‡
 Also known as between a rock and a hard place 
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TABLE 2-1:  SUMMARY STATISTICS FOR CTEP-SPONSORED ONCOLOGY CLINICAL TRIALS BY DEVELOPMENT TIME AND 
ACCRUALS 
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TABLE 2-2:  UNADJUSTED ODDS RATIO FOR ACHIEVING MINIMUM ACCRUAL GOALS (WITH ADJUSTED 
VALUES FOR PROJECTED MINIMUM ACCRUAL AND TYPE OF TRIAL) 
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FIGURE 2-1:  UNDERPERFORMING VS. SUFFICIENT ACCRUING STUDIES BY PHASE 
42
 
Likelihood of Achieving Sufficient Accruals as compared by the total development time for CTEP-sponsored therapeutic Clinical 
Trials, 2000 - 2007 
 
The bars indicate the calculated odds ratios with reference to the median development time.  The vertical lines represent the 95% confidence 
intervals.  The dotted line indicates the referent as defined by the median development time of the sample. 
FIGURE 2-2:  ODDS RATIO OF ACCRUAL SUCCESS ACROSS DEVELOPMENT TIME 
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CHAPTER III 
 
PREDICTING ACCRUAL SUCCESS:  ACCRUAL PERFORMANCE OF NCI-
CTEP SPONSORED CLINICAL TRIALS 
3.1   PREFACE AND RESEARCH MODEL 
 When comparing to the projected accrual performance, actual accrual period of 
studies are often under-estimated while the projected accrual are over-estimated.  
Research in this chapter investigates whether it is possible to forecast eventual clinical 
trial success in terms of achieving the desired accrual performance using early indicators 
of the accrual stage of a clinical trial.  We use two specific accrual milestones:  time-to-
first enrollment and the expected period to achieve the accrual goal.  We control for 
cancer incidences of the study to ensure that the analysis accounts for rarity of cancers.  
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3.2 ABSTRACT 
Background  The need to increase the number of successfully completed oncology 
clinical trials is a well-known issue particularly for trials targeting therapeutic 
applications. As keeping under-accruing clinical trials open to accrual is expensive in 
terms of resources, research time, and use of volunteerism, it is important to understand if 
there are early predictors of eventual study accrual success.  
Methods  Clinical trial records including accruals for all non-pediatric, phase I, I/II, II, 
and III therapeutic studies supported by the National Cancer Institute-Cancer Therapy 
Evaluation Program (NCI-CTEP) that were opened and closed to accrual between 2000 - 
2007 (n=764) were gathered from multiple NCI databases.  Successful clinical trials are 
defined as those achieving achieved 100% or more of the stated minimum accrual goal at 
the time of trial closure.  Two observation points were analyzed per trial: 1) time-to-first 
patient enrollment, which measured the time from study activation to first patient on 
study, and 2) expected-time-to-accrual-goal as measured by the number of months from 
the date of first patient on study to the date the study would achieve its minimum accrual 
goal given the planned accrual rate.  Pearson product moment correlations were used to 
investigate if cancer incidences or mortality related to either observation point.  
Multivariable logistic regression analysis was used to calculate the unadjusted and 
adjusted odds with respect to the likelihood of clinical trial accrual success at the two 
observation points.  All calculations were adjusted for study phase, size of expected 
accrual, and time-to-first enrollment.  
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Results  A total of 81.5 percent (n=623) of the trials did not achieve projected accrual 
goals within the predicted accruing period.  Furthermore, 37.2 percent (n=284) of trials 
failed to achieve the minimum projected accrual at study closure regardless of time the 
trial was open.  Studies that achieved minimum projected accrual by study closure were 
163.3 percent slower than the planned period to achieve the minimum projected accrual.  
Cancer incidences or mortality have no correlation to time-to-first enrollment (p=0.749 
and p=0.152 respectively).  Trials that accrue the first enrollment beyond two months 
(n=379, 49.6%) are statistically significantly less likely to achieve accrual performance 
than those trials that enroll patients under two months (odds ratio; 0. 637, 95% CI: 0.464 
– 0.875, p=0.005).  Of the studies that are open beyond the expected period to achieve the 
minimum projected accrual (n=603), those do not achieve at least 60.0% of the projected 
minimum accrual within the expected period (n=391, 64.8%) have a statistically 
significantly less likelihood of achieving final accruals by study closure (odds ratio; 
0.190, 95% CI: 0.055 – 0.652, p=0.008).  
Conclusions  The time-to-first patient enrollment to a clinical trial as well as accrual 
performance by the expected period to achieve minimum projected accrual are shown to 
be a valid measure to evaluate likelihood of achieving minimum projected accrual.  
Identifying predictors of clinical trial success should be used in conjunction with 
scientific and other evaluations to aid in the decision to support or terminate trials with 
low accruals rates.  
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3.3  INTRODUCTION 
It has been shown that less than one in five cancer clinical trials conducted have 
been published in peer-review journals.
1
 While the selective publication of oncology 
clinical trials with negative results may affect publication rates, a greater and often 
overlooked impact lies with the inability to achieve the adequate accrual, or patient 
enrollment, to evaluate the proposed scientific hypotheses.
2
 With approximately 3-5 
percent of the adult cancer patients in the United States participating in clinical trials, 
individual clinical trials struggle to achieve the necessary accruals.
3
   Under-accruing 
clinical trials can prolong the duration of the trial, delay realization of outcomes, or 
prevent scientific objectives from being achieved.
4
 Unfortunately, it is typical that 
projected accrual rates to a trial are over-estimated, thus causing trials to remain open 
longer than planned.
5, 6
 By prolonging the time is open, unanticipated costs of the clinical 
trial increase as they consume additional administrative and clinical resources.
7, 8
   
Keeping a study open to accrual for longer periods does not guarantee the 
eventual accrual on a study.  Previous observations of non-pediatric National Cancer 
Institute (NCI) Cancer Therapy Evaluation Program (CTEP) sponsored clinical trials 
showed that approximately 40% of the trials did not achieve minimum projected accruals 
by study termination.
9
 The ability to utilize predictors of eventual accrual to a trial will 
allow for better utilization of resources and increase the likelihood that subjects enrolled 
to trials will contribute to the state of medical knowledge.  Therefore, we pose the 
following question:  Are there early clinical trial predictors during the enrollment period 
that may be used to identify and assess the likelihood of a trial achieving accrual goals? 
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In an effort to understand the accrual patterns of oncology clinical trials, we 
conduct a retrospective study of CTEP-sponsored therapeutic trials between 2000 and 
2007.  Studies that are sponsored by National Cancer Institute (NCI) that involve 
collaborative efforts between Cancer Centers, Comprehensive Cancer Centers, 
Cooperative Groups, Consortiums, and industry sponsors must be evaluated through the 
Cancer Therapy Evaluation Program (CTEP).  CTEP review and activate approximately 
500 new clinical protocols annually and is the largest supporter of phase III clinical trials 
sponsored by NCI.
10, 11
 We evaluate CTEP clinical trial accrual patterns throughout the 
entire enrollment period.  Specifically we assess the likelihood that a trial will achieve 
accrual success at two observation points: at the time of first patient enrolment to the trial 
(time-to-first enrollment) and at the end of the expected enrolment time period, i.e., the 
length of time that a trial should have remained open given the projected accrual rate.  
3.4 METHODS  
3.4.1 Sample  
 All therapeutic, non-pediatric, phase I, I/II, II, and III oncology trials requiring 
CTEP evaluation that were activated and subsequently closed to accruals between May 1, 
2000 and December 31, 2007 with complete accrual monitoring data (n=764) were 
eligible for this study.  The CTEP Protocol and Information Office (PIO) provided 
clinical trial characteristics as well as accrual data via the Clinical Data Update System 
(CDUS) and the Clinical Trials Monitoring Service (CTMS), which monitors on a 
monthly basis all patient registrations to publicly sponsored cancer clinical trials.  
Projected accrual rates, projected minimum accrual goal, and activation dates of each trial 
are defined within the trial protocol and collected in the PIO database.   
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Studies that did not have information related to the projected accrual rates were 
excluded (n=24).  If minimum projected accrual goals were not available, the maximum 
projected accrual goal was used (n=2).  Studies that closed with zero accruals at the time 
of study closure were not included in the analysis, as they had no accrual rate (n=42).  To 
investigate if incidence or morality rates impact accrual rates, data on the median age-
adjusted cancer incidence and mortality rate between 2001 and 2005 was collected from 
the Surveillance Epidemiology and End Results (SEER) cancer registry.
12
   
3.4.2  Variables  
 Figure 3-1 provides an illustrative description of key data points during the 
clinical trial accrual period as well as an example of one phase III clinical trial conducted 
by a cooperative oncology group through CTEP.  As reviews for clinical trial 
performance can take place at monthly intervals, the unit of analysis for all time 
information is in months.  
The date of trial activation is the date that CTEP receives notification that the 
study is ready to begin accruing patients from at least one institution that is participating 
in the trial. The date of activation is recorded in months for the purpose of calculations in 
this research and is approximated to the beginning of the month.   
For each study, the date of the first patient enrollment was recorded to the nearest 
month.  The time-to-first enrollment was calculated as the difference in months between 
the date of activation and the date of the first patient enrollment. For example, if a trial 
was opened on the 2nd of the month and the first patient enrolled occurs on the 25
th
, the 
first enrolment would be shown to occur at the first trial review, or one month.  
  49 
The minimum projected accrual of a study is defined within the protocol and is 
typically calculated from a combination of investigator consensus and statistical power 
requirements.   
Rate of accrual in patients per month was specified within the protocol. The 
expected minimum projected accrual period is calculated by dividing the minimum 
projected accrual by the expected rate of accrual.  It is assumed that the rate of accrual is 
linear.  
Final accrual performance was dichotomous with those trials achieving 100% or 
more of minimum projected accrual enrolment at the time of complete study closure 
being defined as successful, and those trials not reaching this threshold as unsuccessful. 
The accrual goal percentage was calculated by dividing the final accrual by the projected 
minimum accrual.  Final accrual of a study was defined by the number of accruals on a 
study at the time the study was completely closed to accrual.    
3.4.3  Observation Points 
 Two different observation points were utilized. First, time-to-first enrollment was 
recorded based on the number of months required from the month of study activation to 
the month of first enrollment.  This point was evaluated in four groups depending upon 
the number of months to enroll the first patient (1-2 months, 2-6 months, 6-12 months, 
and >12 months).  It was of interest to discover if “fast” enrolling trials (i.e., those within 
one or two months), were on a “fast” track for completion. The other periods were 
                                                      
 We acknowledge that studies can close due to a host of reasons, including adverse events, regulatory requirements, or other 
unforeseen situations.  The specific reason for study closure was not available. 
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selected based upon the often-utilized 6-month and 12-month review cycles that 
institutions use to evaluate trial accrual performance.  Analysis at the time-to-first 
enrollment was conducted against the eventual accrual success of a clinical trial at study 
closure.   
 Second, the accrual performance was observed at the estimated time to achieve 
minimum projected accrual.  Studies were analyzed across six equally divided groups 
depending upon the actual accrual performance, as a percent of expected performance, at 
the expected period to achieve the minimum projected accrual (1-19%, 20-39%, 40-59%, 
60-79%, 80-99%, and 100%).  The accrual performance at the expected time to achieve 
the accrual goal is compared against the eventual accrual success of the clinical trial. 
3.4.4  Example Trial 
Figure 1 illustrates an example of a phase III clinical trial contained in the sample.  
The date of activation was on September 2002 with the first patient enrolled on the study 
on January 2003.  Therefore, the time-to-first enrollment was calculated from these two 
dates to be 4 months. 
The projected accrual rate for this study was 29 patients per month and the 
minimum projected accrual was 1058 patients.  Using the time-to-first enrollment as a 
reference point for calculating the expected period to achieve the minimum accrual goal, 
the expected period was 37 months (rounded to the following month to ensure that all 
accruals were accounted for).  Therefore the expected date that the study was to achieve 
the minimum accrual object was set at January 2006.  On January 2006, the milestone at 
which the study was expected to achieve the minimum projected accrual; the number of 
accruals on the study was 195 patients.  The actual accrual performance at the expected 
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period to achieve the minimum projected accrual was calculated by dividing the accrual 
(195) by the accrual goal (1058), which resulted in accrual performance of 18.43% of the 
expected accrual performance.   
At study closure, the final accrual performance was calculated by dividing the 
final accrual of 357 patients by the minimum projected accrual of 1058 patients.  This 
resulted in an accrual performance at study closure to be 33.74%.  Because the final 
accrual performance is 100% of the minimum projected accrual, this study is classified 
as not success.     
This methodology was conducted on the entire sample of 764 clinical trials and 
analyzed collectively. 
3.4.5  Statistical Analysis  
 Descriptive statistics of medians and interquartile ranges (IQR) were used to 
summarize the continuous variables related to accrual characteristics of minimum 
projected accrual and expected period to achieve minimum projected accrual.  A 
maximum 2-tailed alpha of 0.05 was maintained to determine statistical significance.  
Comparison among the trial types (i.e. phases I, I/II, II, and III) were conducted using the 
Kruskal-Wallis test with a post-hoc comparison of statistically significant overall tests 
using Mann-Whitney tests with a Bonferroni-adjusted alpha level of 0.008. 
Categorical and ordinal groups were summarized using univariate and cross-
tabulated frequency distributions. Unadjusted and adjusted odds ratios, along with their 
respective 95% confidence intervals, were obtained using multivariable logistic 
regression analysis.  Adjusted odds ratios were calculated with the addition of adjusting 
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for both phase of the study and the size of the study measured by the minimum projected 
accrual to compensate for any interactive effects.  Statistical analyses were performed in 
SPSS (version 16.0, descriptive and logistic regression). 
3.5  RESULTS 
A total of 764 oncology trials were identified as CTEP-evaluated, therapeutic, 
non-pediatric, phase I, I/II,II,III opened and completely closed to accrual between May 1, 
2000 and December 30, 2007 (Table 3-1).  The sample composed predominately of phase 
II trials (66.0%, n=504), followed by phase I (18.3%, n=140), phase I/II (8.2%, n=63), 
and phase III (7.5%, n=57).  
The median minimum projected accrual goal for all types of trials was 25 subjects 
(IQR: 17-55). The estimated period to achieve the minimum projected accrual was 8 
months (IQR: 5 – 15).  Phase III trials has statistically significant and meaningful 
differences compared to the other types of trials for both the minimum projected accrual 
goal (25 patients for phase I, I/II, and II trials versus 530 patients for phase III trials; 
p<0.001) as well as the projected time to achieve the minimum projected accrual goal (7 
patients/month for phase I, I/II, and II trials versus 40 patient/month for phase III trials; 
p<0.001).   
Overall, 62.8% (n=480) of trials achieved at least 100% of the minimum projected 
accrual goals by closure.  The number of the phase III trials that achieved the accrual 
goals by study closure was statistically significantly lower than non-phase III 
trials(38.6%, n=22; p<0.001).  No statistically significant differences were observed 
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between the trials excluded (n=24) and the study sample with regard to final accrual 
performance (Spearman’s Correlation: p=0.389).  
Only 18.5% (n=141) of the trials achieved the minimum project accrual goal 
within the projected period of time.  Phase III studies had the high proportion of studies 
that met the minimum goal within the expected period with 28.1% (n=16), followed by 
phase II studies with 21.6% (n=109), phase I/II trials with 7.9% (n=5) and phase I studies 
with 7.9% (n=11). 
However, on average, trials achieving minimum projected accruals (n=480) were 
163.3% slower than planned accrual period.  Interestingly, Phase III studies that achieved 
the minimum projected accruals by study closure (38.6%, n=22) met the accrual goal 
within 73.9% of the projected period of time.  This is significantly faster (p<0.001) than 
the other trial phases, where the period required to achieve the minimum projected 
accrual was 241.7%, 216.7%, and 142.9% of the projected period for phase I, phase I/II, 
and phase II trials respectively.   
The trials that did not achieve the minimum projected accruals were open 127.9% 
longer than the expected period to achieve the minimum projected accrual.  Phase III 
studies that did not achieve the minimum projected accrual on median closed prior to the 
expected period (47.2%). Phase I, I/II, and II trials opened beyond the expected period by 
213.3%, 150.0%, and 130.8% respectively.  
When comparing trials that achieved the accrual goal at closure to those that did 
not, phase I and II trials that closed without achieving the minimum projected accrual had 
a larger accrual requirement than those trials that did achieve the accrual goal (phase I: 
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p=0.009, phase II: p>0.001).  Furthermore, studies that achieved accrual success had a 
significantly shorter projected accrual period compared to studies that did not achieve 
accrual success (phase I, p>0.001; phase I/II, p=0.017, phase II, p>0.001, phase II, 
p=0.003).     
To investigate the relationship between time-to-first enrollment with the eventual 
accrual success of a study, multivariable logistic regression analysis was conducted to 
calculate the likelihood of achieving success.  Clinical trials were stratified by the number 
of months required to accrue the first patient from study activation.  The likelihood of 
achieving the accrual goal was highest for those studies that accrued the first patient with 
the first two months of enrollment (Table 3-2).  All subsequent groups had a statistically 
significantly decreasing likelihood of achieving their goals compared to this referent 
group.  Relative to trials that accrued the first participant within the first two months, 
trials taking between 2 and 6 months were statistically significantly less likely to achieve 
the minimum projected accrual (OR0.637; 95% CI, 0.464 – 0.875; p=0.005).   Studies 
with the first accrual between 6 and 12 months as well as studies that had the first accrual 
beyond 12 months had an decreased and statistically significant likelihood of obtaining 
the minimum projected accrual at the time of study closure compared to the referent 
(OR0.208, 95% CI, 0.056 – 0.459; p=0.001).   
The cancer incidences rate and the cancer mortality rate based on the disease 
focus of the clinical trial was collected from the SEER cancer registry and analyzed with 
respect to the time to first patient (Table 3-3).  No statistical difference between cancer 
incidence or mortality and the time to enroll the first patient was observed (p=0.749 and 
p=0.152 respectively). The relationship between month to first patient and achieving 
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accrual successes held after adjusting for the minimum projected accrual of the trial, 
phase of the study, and cancer incidences by disease.  
Of the studies that were open beyond the expected period to achieve the minimum 
projected accrual (n=603), the analysis of the actual accrual at the projected period 
required to achieve the minimum projected accrual was conducted with respect to accrual 
success (Table 3-4).  Relative to studies that have achieved at least 80% of the minimum 
projected accrual within the projected period, trials with <60% of the minimum projected 
accrual have a statistically significant less likelihood of achieving the minimum accrual 
goals (OR 40% - 60% of minimum projected accrual: 0.190, 95% CI, 0.055 – 0.652, 
p=0.008, OR 20% - 40% of minimum projected accrual:  0.121, 95% CI, 0.036 – 0.409, 
p=0.002; OR 0% - 20% of minimum projected accrual: 0.065, 95% CI, 0.019 – 0.227, 
p>0.001).  A total of 391 trials (64.8%) fell within the category of studies with <60% of 
the minimum projected accrual.   
Given the previously established differences among phase, minimum projected 
accruals, and time-to-first enrollment on a study, the likelihood values were also then 
adjusted for these three variables.  No statistically significant differences in the 
relationship between the percent of accrual achieved at the observation point were 
observed after adjusting for the additional factors.   
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3.6  DISCUSSION  
The analysis of National Cancer Institute Cancer Therapy Evaluation Program 
oncology trials reveals that a small number of trials (11.1%, n=85) are able to achieve the 
minimum projected accrual within their planned accrual period.  Almost two out of five 
trials in the sample did not achieve the minimum projected accrual by study closure.  For 
phase I, I/II, and II studies did that achieve the minimum projected accrual goal, the 
project accrual time period is often under-estimated when compared to the actual time 
required.  For the phase I, I/II, and II studies that did not achieve the minimum projected 
accruals with the expected time period, trials are opened to patient accrual 213.8%, 
150%, and 130.8% longer than the expected to achieve the minimum projected accruals 
respectively.  Phase III studies are unique because a higher percentage (61.4%, n=35) of 
trials closed without achieving the minimum projected accruals; however, trials that 
either close without achieving the minimum accrual goals or do achieve the minimum 
accrual goals do so before their expected time period.   
We provide multiple observation points during the accrual period of a clinical trial 
that can be utilized to access the likelihood of a trial achieving minimum projected 
accrual.  The findings demonstrate that the accrual performance of a clinical trial can be 
predicted as early as the time-to-first enrollment on a trial.  Almost half of the studies (n= 
379, 49.6%) enroll the first patient outside the first two months of the study enrollment, 
which translates into those studies having a statistically significantly lower odds of 
successfully achieving the minimum projected accruals at study closure (odds ratio: 
0.637) when compared to the referent.   
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Furthermore, trial accrual performance can also be predicted at the expected 
period to achieve the minimum projected accrual goal.  Even with the use of a more 
liberal definition for projected period to achieve the minimum projected accrual, a large 
percentage of studies (64.8%, n=391) fall into the category of not achieving at least 60% 
of the minimum projected accruals by the projected period and thus have a decreased 
likelihood of achieving the minimum projected accrual by study closure.  
Adequate accrual to clinical trials is the most fundamental and easily quantifiable 
measure of performance for a clinical trial.
6
 The ability to monitor clinical trial accrual 
performance allows for greater support for earlier decisions to be made regarding the 
management of clinical trials.  Identifying studies with a decreased likelihood of 
achieving the minimum projected accrual may lead to trial decisions.  Decisions can be 
made to add additional resources and/or funding to implement actions that may improve 
accruals, such as opening a study to multiple institutions, or closing studies early to 
release resources to support other trials with a greater likelihood of achieving their 
accrual goals. We do not advocate making decisions solely on accrual performance 
during these two observation points; rather, we advise utilizing accrual-monitoring 
metrics to complement the scientific judgment of completing accruals to each individual 
clinical trial when making decisions regarding the management of trials.  
Closing studies due to poor accruals is not ideal in any circumstances.  Large 
amounts of time and effort are consumed on the development of a clinical trial with poor 
accrual and the ultimately do not allow the intended scientific endeavor to come to 
fruition.
13-15
 Patients maybe volunteering to participate on a study enroll on studies that 
do not help advance the state of medicine.
9
 Sunk cost bias ingrained from the efforts 
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committed towards the development of the clinical trial can often jeopardize current 
resources to be allocated to poor accruing trials trial even beyond the likelihood of 
successfully completing the accrual requirements.   
Assuming the cost to physicians for data management and other research 
expenses associated with enrolling a patient in a cancer clinical trial approximately $2000 
per subject,
16
 the 10746 participants enrolled on studies that closed without achieving the 
minimum projected accruals translate to almost $21.5M directed to studies that have 
limited contribution towards science and clinical practice.  This amount does not include 
the unanticipated costs associated towards studies that open to accrual beyond the 
expected period of time and do not ultimately achieve the projected accrual goals in the 
form of nonclinical costs such as administrative support, IRB and FDA/regulatory review 
renewal fees, and recruitment fees.
7, 8, 17
 How much of this allocated resources could have 
been directed towards other clinical trials earlier to support other endeavors?  If the goal 
of conducting clinical trials collectively is to be able to provide the necessary scientific 
and statistical findings to support medical outcomes and to improve the standard of care 
to the general population given the limited amount of patient participation and resource, 
clinical trial managers must be able to make decisions earlier in both the development 
and the conduct of a clinical trial with regard to supporting or discontinuing studies.   
The results presented in this paper are limited by the fact that findings are 
applicable for only NCI-CTEP studies. Perhaps similar accrual patterns may be observed 
across other medical domains and the question should be further investigated.  
Furthermore, there are numerous reasons why studies have low accrual or why studies 
close to accrual prior to achieving the minimum projected accrual.  Continued research 
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should be conducted to identify characteristics that are attributed to studies with low 
accrual in order to reduce the occurrence of studies being closed without any sufficient 
accrual needed to gain the intended scientific objective.  
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TABLE 3-1:  SUMMARY STATISTICS FOR NCI-CTEP SPONSORED ONCOLOGY CLINICAL TRIALS BY ACCRUAL PERFORMANCE 
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TABLE 3-2:  UNADJUSTED ODDS RATIO FOR ACHIEVING THE MINIMUM PROJECTED ACCRUAL BY STUDY CLOSURE STRATIFIED 
BY THE TIME-TO-FIRST ENROLLMENT (WITH ADJUSTED VALUES) 
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TABLE 3-3:  DISEASE TYPE BY SAMPLE SIZE, TIME-TO-FIRST PATIENT, INCIDENCE, AND MORTALITY 
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TABLE 3-4:  UNADJUSTED ODDS RATIO FOR ACHIEVING THE MINIMUM PROJECTED ACCRUALS BY STUDY CLOSURE STRATIFIED 
ACCRUAL PERFORMANCE AT THE EXPECTED PERIOD (WITH ADJUSTED VALUES)
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FIGURE 3-1:  DEFINITION FOR OBSERVATION POINTS AND TIMING ANALYSIS 
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CHAPTER IV 
 
IMPACT OF CLINICAL TRIAL CHARACTERISTICS ON DEVELOPMENT 
TIME OF NCI-CTEP SPONSORED CLINICAL TRIALS 
4.1   PREFACE AND RESEARCH MODEL 
 The time to develop a NCI-CTEP sponsored clinical trial can take approximately 
26 months to complete.
1
 In the previous research, we have shown that increased 
development time has an inverse affect on the likelihood of achieving accrual success.  
Research in this chapter identifies clinical trial characteristics that impact this barrier to 
clinical research effectiveness.  We extract characteristics from four different categories 
of characteristics:  Demographics, Study Design, Study Agents, and Study Reviews.  
Understanding which characteristics attribute to development time is the first step to 
reducing the overall development time.  
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4.2 ABSTRACT 
Background  The median time required to develop an NCI-CTEP sponsored oncology 
clinical trial from initiation of concept to enrollment of first patient on trial has been 
found to consume a significant amount of calendar days.  Furthermore clinical trials with 
greater development time have shown a decreased likelihood of achieving necessary 
accrual levels. This study examines the relationship between development time and the 
clinical trial characteristics.  Understanding the underlying characteristics of clinical trials 
that impact development time will result in a better understanding the barriers to rapid 
clinical trial development. 
Methods  A total of 1030 National Cancer Institute (NCI) sponsored therapeutic 
oncology clinical trials through the Cancer Therapy Evaluation Program (CTEP) opened 
to patient accrual in an eight-year period (1/2000 – 12/2007) were investigated.  Trial 
characteristics and development times were collected through the Protocol Information 
Office (PIO) of CTEP.  Development time is defined as the difference between day that a 
protocol is submitted for concept review and the day that the clinical trial is activated, or 
opened for patient enrollment.  Due to the extensive non-normality of the variable 
distributions, all data were ranked. Because Phase III trials have meaningfully different 
levels of trials characteristics, analyses were split between Phase III and non-Phase III 
trials. Multivariate analysis using linear regression of the ranked characteristics was used 
to calculate the variance in ranked development time for both data sets. .   
Results  Clinical trial characteristics accounted for 24.9% of the variation in development 
time for Phase I, I/II, II trials.  A total of ten clinical trial characteristics were identified to 
contribute to the explaining the variance in development time.  For phase III clinical 
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trials, clinical trial characteristics accounted for 30.2% of the variance in development 
time.  Four clinical trial characteristics related towards explaining the development time.  
A multivariate linear regression analysis revealed that protocol and concept review was 
the most pronounced determinant of development time for all clinical trial phases.  
Conclusion  A number of clinical trial characteristics have been identified as predictive 
factors towards predicting the time to develop a clinical trial.  Continued research to 
identifying additional clinical trial characteristics is needed to address the variance in 
development time.  
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4.3  INTRODUCTION 
Challenges to improve the speed and efficacy of oncology clinical trials have been 
paramount within the National Cancer Institute (NCI).
1
 Translating a research idea into a 
operational phase III clinical trial have been found to be an complex endeavor requiring 
nearly 26 months to prepare.
2, 3
 Every clinical trial developed is meticulously planned, 
with no less than six reviews by multiple participants.2-4 Additional reviews are required 
by trials sponsored by external organizations such as the NCI as well as at the multiple 
institutions that may be involved in accruing patients on the trial.5 In a span of over two 
years for which a clinical trial is undergoing development, how much of the state of 
science has changed or what new trends in medicine may have occurred? Long trial 
development time can cause unnecessary delays before any potential results from the 
clinical trial may become available.  The progress of clinical research evolves quickly 
and findings from the latest research results can often cause a trial under development 
becoming obsolete.6 Competing trials also may occur because the development time 
cannot be predicted and may be completed a the same time as a separate trial utilizing the 
same patient population.7 Excessive time to develop a clinical trial not delays the 
progress of cancer research, but it has also been found to be barrier in achieving success 
in terms of accrual goals.8 Observations have estimated that approximately two in every 
five NCI clinical trials attempted fail to achieve the minimum accrual goal necessary to 
statistically support the intended scientific objective. 
A first step towards reducing the development time of a clinical trial is to identify 
the underlying characteristics that may be correlated to development time.  Identifying 
such critical trial characteristics can also begin to explain the variance in estimating time 
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necessary to effectively manage clinical trial development. From the perspective of the 
principal investigator or study chair who is designing the clinical trial, it is important to 
have an understanding of the cost, with respect to development time, that various trial 
characteristics may have, and the potential impact of such factors on the likelihood of 
completing accruals to the trial.  Likewise, directors of medical institutions, such as NCI-
CTEP, are interested in development time as it impacts the status of overall their portfolio 
of the clinical trials.9 
This research identifies if general clinical trial characteristics can be utilized as 
indicators to estimate clinical trial development time.  This research establishes a baseline 
framework to understanding and identifying barriers to long development time of 
oncology clinical trials sponsored by CTEP. 
4.4  METHOD 
4.4.1  Study Sample 
 The study sample was all therapeutic, phase I, I/II, II, and III oncology trials 
sponsored through NCI-CTEP and opened to accrual between January 1, 2000 and 
December 31, 2007.  Trials submitted to NCI-CTEP from Cancer Centers, 
Comprehensive Cancer Centers, Cooperative Groups, Consortiums, and government 
agencies (i.e. National Institutes of Health and National Cancer Institute Branches) were 
eligible for this study (n=1046).  Trials with incomplete timing data, specifically the date 
of receipt of the concept by NCI-CTEP, were excluded (n=409) due to the inability to 
calculate total development time. 
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To obtain the characteristics of the clinical trials in the sample, we collected 
information concerning both concepts and protocols per clinical trial from the CTEP-PIO 
database.  Trials that seek NCI support are required to submit a concept or letter of intent 
(LOI) for evaluation by the CTEP scientific committee prior to pursuing the development 
of the clinical trial.  Once the concept is approved and the clinical trial is developed, the 
clinical trial is required to be submitted to NCI-CTEP for scientific review of the 
completed protocol.  A clinical trial can only be activated and ready for patient accrual 
provided that all the necessary reviews have been conducted.  (For a detailed process to 
develop a clinical trial with CTEP support, we refer you to Dilts et al.
5
)  A central 
repository of clinical trials maintained by the CTEP-Protocol Information Office (PIO) 
tracks a host of characteristics and clinical trial information. We compiled a 
comprehensive list of characteristics for each of the trials in the database on the available 
data.  
4.4.2  Characteristics Organized in Factor Grouping 
A total of 78 clinical trial characteristic variables were retrieved from the CTEP 
PIO-database (Table 4-1).  Fifty-four (54) variables were not used for the analysis 
because of duplicate variables, variables unrelated to development time, or inconstant 
coding of the data.  Three (3) variables were used to filter the final sampling set, and 18 
variables were used to as the specific clinical trial characteristics for our research (Figure 
4-1).  The characteristics were categorized a priori into 4 different factor groups for ease 
of understanding:  clinical trial demographics, scientific design, study agents and 
regulatory requirements, and scientific/ethical reviews (Table 4-3).  Characteristics that 
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were identified but had 10% observations within the cohort were excluded from in the 
study.  
Clinical Trial Demographics, the first factor grouping, included characteristics 
related to general characteristics of the trial such as phase and organization.  
Characteristics also included operational characteristics such as whether the trial was an 
NCI-solicited trial or an expedited trial.  The NCI-CTEP can provide a solicitation for 
Phase I, I/II, and II trials in order to identify areas that are deemed to be scientifically or 
strategically important towards the direction of cancer research.  Institutions can respond 
to NCI-CTEP solicitations by providing a letter of intent for review thus beginning the 
clinical trial development process.  NCI-CTEP can expedite trials (particularly phase III 
trials) that are identified as having high importance or require timeliness to enrolling 
patients.  Trials designated for the NCI expedited developmental process are assigned 
tighter deadlines for which reviews and revisions must be conducted.  Also included in 
the clinical trial demographic characteristics was a variable that designates the trial focus 
on hematopoietic diseases such as leukemia, lymphoma, and myeloma or non-
hematopoietic diseases, specifically solid tumors.  The characteristic that identified 
pediatric trials among the cohort of trials was also included in clinical trial demographic 
category. 
The Study Design factor group included trial characteristics related to the protocol 
scientific issues.   Included in the scientific design group are variables related to trial size 
such as projected patients per month and projected minimum accrual.  Both variables 
were specified in protocol during trial development.  Correlative studies may also be 
conducted in combination with the clinical trial.  These are secondary studies that may be 
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conducted prospectively, retrospectively, or conducted in conjunction with the treatment.  
Also with this group were trial characteristic of: additional treatment approaches beyond 
drug/therapeutic agents, specifically radiation therapy, surgery, stem cell transplant, gene 
therapy. 
The third factor group, Study Agents Information, included variables that related 
to the therapeutic agents being used for the trial.  Often times, trials examine whether a 
new treatment option compares with the existing treatment, or standard of care option.  
Factors included in this group include the number of therapeutic agents as well as the 
number of investigational agents that will be used.  Investigational agents require 
additional Food and Drug Administration (FDA) involvement that may add additional 
reviews and processes before clinical approval.    
The final factor group, Study Reviews factor group included characteristics of the 
number of reviews required to obtain approval by NCI-CTEP scientific review 
committee.  Scientific reviews are conducted when a trial is submitted for review as a 
letter of intent (for phase I, I/II, and II trials) or as a concept (for phase III trials).  Upon 
approval of a concept, the idea is developed into a protocol for review and then 
subsequently submitted for a complete scientific review.  Often, the outcome of a review 
requires additional revisions to address stipulations from the review committee.
5
 
Additionally, the number of times a clinical trial have been reviewed and received an 
outcome of disapproval is also tracked.  “Disapproval” outcomes are the harshest 
outcome whereby the trial is considered to have issues of major scientific deficiencies; 
yet the institution or the principal investigator has the option to resubmit the clinical trial 
for further review.  NCI has also implemented the use of a centralized-institutional 
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review board (CIRB) that reviews clinical trials for ethical considerations.  The CIRB 
was designated to reduce the amount of redundant processing steps created by multiple 
ethical reviews conducted for multi-institutional trials.
10
 
4.4.3  Statistical Analysis 
Based on a priori knowledge of the uniqueness of phase III trials compared to 
other clinical trials with respect to development time, trial size, and accrual performance, 
the analysis of phase III trials was completed separately from the other trials.
8, 11
 
Descriptive statistics of the characteristics by the two groups are summarized by median 
and interquartile ranges (IQR) for continuous variables and occurrences and percent of 
sample for discrete variables. 
Because of the high non-normality of the data, all variables were transformed by 
rank with mean rank values assigned to cases with equal values. Hierarchical multivariate 
linear regression model was used to examine the association between the dependent 
variable of clinical trial development time against the characteristics within the four 
groups: clinical trial demographics, study design, study agents, and scientific/ethical 
reviews.  Regression results were analyzed by each blocked category.  A final regression 
model was created based on the significant findings from the regression analysis.  The 
results are presented by ranked transformation for ease of interpretation. Statistical 
analyses were performed in SPSS (version 16.0, descriptive and hierarchical multiple 
linear regression). 
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4.5 RESULTS 
A total of 1031 NCI-CTEP sponsored clinical trials that were opened to accrual 
between 1/2000 and 12/2007 met inclusion criteria.  Phase II trials (n=526, 51.0%) 
constituted the majority of the trials followed by phase I (n=262, 25.4%), phase III 
(n=152, 14.7%), and phase I/II (n=91, 8.8%). 
Clinical trials were subdivided by phase III and non-phase III trials.  Figure 4-2 
illustrates the finding that phase III trials are statistically significantly greater in 
development time compared to trials of other phases (Mann-Whitney: p0.001).   For the 
cohort group focused on non-phase III clinical trials, it was observed a priori that there 
was no significant differences in development time between phase I, I/II, and II trials 
(p=0.530).  Other trial characteristics related to phase I, I/II and II trials as well as to 
phase III trials are shown in table 5. 
4.5.1  Phase I, I/II, II Clinical Trials 
Table 6 reflects the findings from the hierarchical multiple regression results of 
phase I, I/II, and II trial characteristics as predictors of the variance of trial development 
time.  Analysis between phase and treatment arms showed that there was a significant 
correlation between phase and treatment arms (Pearson Correlation=-0.660, p0.001), so 
treatment arm used in the regressions and phase I, I/II, II was excluded from further 
analysis.  Other characteristics are not meaningfully correlated to phase (Pearson 
Correlation>0.40).   
The first set of analyses was to explore the relationship between clinical trial 
demographics and development time.  The presence of pediatric (p=0.011), solicited 
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(p0.001), and hematopoietic  (p=0.010) trials accounted for higher trial development 
time.  However, there was no statistically significant relationship of organization on the 
development time (p>0.05) for these trial phases.  Characteristics related to trial 
demographics accounted for 2.7% of the development time, which while statistically 
significant (p=0.001), was not meaningful.  
The second analysis used hierarchical multiple regression modeling by regressing 
study design factors onto clinical trial demographic factors with respect to development 
time. This showed an increase in variance explained (adjusted R
2
=0.080,  = 0.053, 
p0.001).  In addition to the previously mentioned characteristics, the study design 
characteristics that statistically contributed positively to the prediction of increased 
development time included trials that involved radiation therapy, surgery, stem cell 
transplant, image directed therapy, and/or genetic transplant (p0.001) and the number of 
correlative studies (p0.001).  Interestingly, trials that had greater projected accrual rates 
(in terms of patient per month) negatively and statistically significantly impacted the 
variance in development time (p=0.029).    
The third analysis explored whether the addition of study agents had an impact on 
development time in addition to clinical trial demographics and study design.  The 
presence of investigational agents had a positive impact on the development time 
(p=0.001) but the number of commercial agents did not have any statistically significant 
effect (p=0.227).  Adding the additional characteristics of study agents increased the 
amount of variance explained, or adjusted R
2
 to 9.0% ( = 0.01 from previous model).   
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The final analysis assessed the impact of scientific review factors, in addition to 
the previously mentioned factors.  Both the number of concept reviews and the number of 
protocol reviews had a statistically significant positive impact on the development time of 
a clinical trial (p0.001).  The inclusion of scientific review as a predictive factor did not 
drop any of the previously mentioned factors that contributed to assessing the variance of 
development time. Adding the characteristics of number of concept reviews and number 
of protocol reviews accounted for 24.9% of the variance in development time, ( = 0.159 
from previous model).   
A total of ten characteristics were identified as having a statistically significant 
impact on total development time (Pediatric, NCI-Solicitation, Hematopoietic Diseases, 
Therapeutic Arms, Correlative Studies, Projected Accrual Rates, Additional Treatment 
Approaches, Investigational Agents, Concept Reviews, and Protocol Reviews) for non-
phase III oncology trials.  A final hierarchical multiple regression model including the 
characteristics that were identified to be statistically significant in explaining the 
development time variance as Block 1 and the remainder of the variables in Block 2 was 
conducted to verify the relationship of the characteristics on development time.  The ten 
identified factors characterized in Block 1 represented 24.8% of the variance in 
predicting development time for non-phase III trials, while the remaining variables in 
Block 2 accounted for the remaining 0.1% of the variable thus confirming the findings of 
the analysis.  
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4.5.2  Phase III Clinical Trials 
Table 6 summarizes analyses of phase III clinical trial characteristics on 
development time variance by means of hierarchical multiple regression.  Because the 
overwhelming majority of NCI-CTEP supported Phase III clinical trials are conducted in 
the cooperative group setting (n=151, 99.3%), the variable of organization was excluded 
from the analysis. 
The first set of analyses of phase III trials explored the impact clinical trial 
demographics factors on development time.  A linear regression model resulted in 
predicting 5.8% of the development time variance (p=0.008).  Pediatric trials were found 
to contribute to an explaining an increase in development time (p=0.036) while studies 
that were expedited through the development process was shown to have a decreasing 
impact on development time (p=0.007).  
The second set of analysis explored whether the addition of the trial study design 
factor improved the underlying hierarchical multiple regression results.  An increase of 
2.9% in variance explained in the development time resulted in the second analysis 
accounting for 8.7% of the variance (p=0.008).  An increase in development time was 
explained by trials that involve radiation therapy.  Expedited trials were the only variable 
from the previous model that contributed to explaining variance in development time 
(p=0.008). 
The third set of analyses added the factor related to study agents involved, 
particularly the number of investigational and commercial agents being used, to the 
previously established model.  The addition of both characteristics did not statistically 
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significantly predict development time, but the overall regression model accounted for a 
total of 10.2% of the variance in development time ( = 0.015 from previous model; 
p=0.006).  
The final set of analysis for the hierarchical multiple regression model included 
the previous characteristics in addition to characteristics related to the scientific and 
ethical reviews factor.  Both concept and protocol reviews resulted in being particularly 
strong indicators of development time (p<0.001 for protocol reviews, p=0.009 for 
concept reviews).  The option to submit a clinical trial through CIRB did not influence 
the variance in the development time (p=0.664).  In the final model, surgical trials 
positively impacted the development time (p=0.026) while expedited trials were found to 
explain a decrease in development time (p=0.004).  All other factors were not statistically 
significant in the model.  With the addition of scientific and ethical review 
characteristics, there was a marked increase from 10.2% of the variance accounted for in 
the previous model to predicting 30.2% of the variance ( = 0.20 from previous model). 
The characteristics of expedited trials, surgical trials, number of concept reviews, 
and number of protocol reviews were found to be statistically significant in predicting the 
variance of development time.  Further verification of the final model was created by 
analyzing these four characteristics in Block 1 to assess total variance accounted for.  The 
other characteristics were entered in Block 2 to ensure that the model was complete.  The 
four identified characteristics accounted for 28.1% of the variance in predicting 
development time while the remaining 11 variables accounted for 2.1% of the variance.     
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Overall, characteristics related to scientific and ethical reviews contributed the 
greatest explanatory support for the variance found in development time for both phase 
III and non-phase III trials (Figure 4-3).  The analysis of phase III clinical trials identified 
only 4 statistically significant factors, but accounted for a greater variance of 
development time compared to phase I, I/II, and II trials.   
Beta weights for all factors are shown in Table 4-4.  
4.6  DISCUSSION 
This research provides a comprehensive investigation of the available 
characteristics that are recorded concerning oncology clinical trials in development under 
the CTEP mandate over an eight-year period.  With over 70 variables available in the 
CTEP-PIO database, a total of eight variables were identified to contribute to the 24.9% 
of development time variance for phase I, I/II, and II trials.  For phase III trials, four 
variables were identified to statistically account for 30.2% of the total development time 
variance. Further research is needed to what additional characteristics account for the 
development time.  
The identified characteristics that relate to predicting development time variance 
can be grouped into two types:  process-driven variables and trial-derived attributes.  
Process-driven characteristics are variables that can be changed based on decisions 
(either by the institution or NCI-CTEP) that are made at the onset of development such as 
the option to expedite a trial, solicit ideas for a trial, append a correlative study, reduce 
the number of reviews, and option to involve CIRB into the development.  Trial-derived 
attributes are variables that are dependent on the trial itself as driven by scientific or 
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statistical requirements and hence cannot be changed without changing the underlying 
trial hypothesis and/or scientific objective.  These characteristics include: number of 
treatment arms, disease focus of the trial, targeted patient population (i.e. pediatric trials), 
and projected minimum accruals. 
Trial-derived attributes can only be used as passive predictor of development time 
to provide reasonable timelines and expectations as to when a trial will available to enroll 
participants.  Such characteristics can be used to manage the portfolio of developing and 
ongoing clinical trials to help avoiding incidences such as trials being blocked because 
another, similar study is underway, and resource requirements to support future trials. 
Allowing for factors to support the prediction of development time extends portfolio 
management across a rolling-time horizon where forecasting the demands and 
requirements of future clinical trials can be accomplished.
12
 
It is of interest to focus on characteristics that are process-driven variables where 
proactive decisions can be made which impact development time.   From our research, it 
is found that both the decision to develop clinical trials through NCI-solicitations as well 
as to expedite trial a have a positive affect on decreasing clinical trials.  With the 
knowledge that PIs may be able to complete the development of CTEP-sponsored trials 
provided that it is in response to a solicitation of idea may be help increase the number of 
trials that fit a strategic need or population demand set forth by the NCI.  It is also shown 
that the expedited trials impact by decreasing development time.  This finding is 
significant in the fact that it is observed that both the PI as well as CTEP should be able 
to fulfill specified timelines if they are defined early.  Unfortunately, expedited trials still 
require a median of 464 calendar days to develop, which is approximately the same time 
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as a phase I, I/II, or II trial.  Furthermore, it is unknown what the adverse impact on the 
development of other clinical trials in progress by such expediting as the resource 
requirements may be tied up on expedited trials required to satisfy the shorter timelines.  
We have shown that the number of reviews at the concept and the protocol 
development stages are strong predictors of the overall development time.  Findings from 
past research have shown that the process to complete a clinical trial can require 
numerous loops whereby processes must be repeated until approval is obtained.
13
 
Looping through the development process is a symptom of administrative barriers that 
are present within the institution and the interface between these institutions and external 
agencies such as CTEP.
4
 The study findings presented here only account for the number 
of scientific reviews by the CTEP protocol review committee that is found to require a 
median 6-7 reviews (Table 4-3).  Reviews of the clinical trial in development do not 
include the interchange within the institution and the PI, the industry sponsor, the Food 
and Drug Administration, or correspondence regarding financial or contract negotiations.  
Further research must be conducted to understand the underlying rational as to why 
clinical trials require the so many re-reviews. 
Previous studies have shown that development time has a significant negative 
relationship on accrual performance.  In addition to continuing to identify characteristics 
that impact development time, further research is suggested to identify better clinical trial 
predictor characteristics and to study their impact on the accrual performance of the trial. 
It is important to note that these research findings are only applicable to NCI-
CTEP sponsored oncology clinical trials.  Furthermore, the variables that are used in the 
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analysis do not include any scientific evaluation into the quality of the trial nor the 
current state of science at the time the trial was developed.  However, the findings of this 
research provide a strong foundation and framework to uncovering the barriers to the 
recently discovered barrier to development time.   
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TABLE 4-1A:  AVAILABLE CONCEPT-RELATED CLINICAL TRIAL CHARACTERISTICS COLLECTED IN THE CTEP-PIO TRACKING 
AND MONITORING DATABASE 
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TABLE 4-1B:  AVAILABLE PROTOCOL-RELATED CLINICAL TRIAL CHARACTERISTICS COLLECTED IN THE CTEP-PIO TRACKING 
AND MONITORING DATABASE
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TABLE 4-2:  CLINICAL TRIAL VARIABLES BY FACTOR GROUPINGS 
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TABLE 4-3:  CLINICAL TRIAL DEMOGRAPHICS FOR PHASE I, I/II, II TRIALS AND PHASE III TRIALS 
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TABLE 4-4:  HIERARCHICAL MULTIPLE REGRESSION RESULTS FOR CLINICAL TRIAL 
DEVELOPMENT TIME REGRESSED ON CLINICAL TRIAL CHARACTERISTICS BY FACTOR 
GROUPINGS FOR NCI CTEP-SPONSORED CLINICAL TRIALS
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FIGURE 4-1: SELECTION AND FILTERING CRITERIA UTILIZED IN IDENTIFYING 
VARIABLES IN ANALYSIS 
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Phase III vs Phase I, I/II, II (Mann- Whitney two-sample P0.001) 
Phase I, vs Phase I/II, vs II (Kruskal-Wallis n-sample P=0.530) 
FIGURE 4-2: DEVELOPMENT TIME OF CLINICAL TRIALS BY PHASE 
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FIGURE 4-3:  COMPARISON OF FACTOR GROUPS BY PHASE 
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CHAPTER V 
 
CONCLUSION 
 
This research investigated the impact of oncology clinical trial success indictors 
that occur during pre-activation (or the period required to develop a clinical trial) as well 
as early post-activation indicators as they relate to the likelihood of a clinical trial 
achieving accrual success.  The research was divided into three main components: 1) the 
relationship between trial development time and accrual success, 2) the relationship 
between time-to-first patient enrollment to the clinical trial and the expected accrual 
performance with accrual success, and 3) the characteristics of clinical trials that relate to 
development time.  The research findings provide insight into factors related to the 
success of achieving accrual goals as well as clinical trial characteristics related to 
development time and it broadens the horizon for future research in the areas of design 
and development stage of clinical trials. 
5.1   IMPACT OF DEVELOPMENT TIME ON ACCRUAL SUCCESS 
In Chapter II, development time was found to have a statistically significant and 
meaningful negative impact on the likelihood of a clinical trial achieving success in terms 
of its accrual goal.  With regard to research investigating improvements to translational 
science, this finding uncovers barriers to clinical research effectiveness during pre-
activation time and processes.  Research focusing on causes of low clinical trial accrual 
must acknowledge that pre-activation clinical trial factors, such as development time, 
also impact enrollment, in addition to patient perception and physician’s effort to recruit.
1
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My research shows that development time can be used as an indicator that 
provides quantitative support for decisions to continue or terminate a clinical trial during 
its development and immediately post-activation. Specifically, for NCI-CTEP sponsored 
oncology clinical trials, trials that extend development time beyond 12 months have 
decreasing likelihood of accrual success the more development times increase.  
Essentially, once an idea is conceived, there is a “countdown clock” during which the 
trial idea remains of interest and it avoids becoming obsolete, both in terms of scientific 
and popularity to the oncology community.  
5.2   EARLY PREDICTORS OF ACCRUAL SUCCESS 
In Chapter III, which studied early post-activation indicators of oncology clinical 
trial accrual success, it was found that both time-to-first enrollment as well as accrual 
performance at the expected deadline were predictors of achieving accrual success.  
These findings create opportunities conduct prospective observation points on clinical 
trials rather than retrospective analysis of completed trials.  Public policy and health care 
management researchers can utilize these critical milestones to investigate what actions 
were conducted on clinical trials to improve accrual rates and whether these were 
effective in impacting achievement of accrual success.  Preliminary findings of this 
research also hint at evidence that both the incidence of cancer and the mortality of 
cancer in the general population do not impact accrual rates.  Therefore, the barriers to 
clinical trial accrual success of a study are found in other factors beyond patient 
population demand or urgency by cancer type. 
Additionally, the second stream of research provides two well-defined milestones 
where the evaluation of clinical trial progress can be conducted.  Time-to-first enrollment 
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is a milestone that all studies must fulfill (with the exception of studies that are so 
unsuccessful that they do not enroll a single participant) and is a standardize evaluation 
point that is easily measured.  Studies that do not enroll the first patient as early as two 
months begin to show statistically significant signs of decreased likelihood in achieving 
accrual success.  Early interventions of strategically or scientifically important studies 
therefore should be conducted as early as two months after opening.  For example, 
critical studies that do not achieve this first accrual milestone may elect to begin efforts to 
extend a study to a multi-institution setting such as through Community Cancer Oncology 
Program (CCOP), a network that enables an increased number of patients and physicians 
to participate on a clinical trial, in order to increase the accruals.
2
  
Expected time to fulfill the minimum projected accrual is a milestone that is 
defined by the principal investigator, trial statistician, and those involved with the 
protocol development.  Findings from this dissertation show that few clinical trials are 
able to achieve the projected accrual performance goal within the pre-defined schedule.  
Decisions may be supported to either reward clinical trials for able to accruing the desired 
number of patients within the expected period of time, or punish those that do not.  
Identifying two accrual rate milestones sets the foundation for the application of portfolio 
analysis towards the health care setting of clinical trials management.  Clinical trials 
accrual progress can be systematically evaluated and quantifiably measured with regard 
to likelihood of achieving the intended accrual goals. 
5.3   CHARACTERISTICS IMPACTING DEVELOPMENT TIME 
This research takes the initial steps in uncovering factors related to long 
development time based on the findings from Chapter IV.  The research provides an 
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initial framework and methodological approach to understand the factors that are related 
to development time.  Continued research can build off these findings by identifying 
additional factors that related to development time including subjective factors and 
currently unmeasured factors.   
Practical applications of this research identify two types of factors or 
characteristics that impact development time: 1) Process-driven characteristics and 2) 
Clinical trial-derived attributes.   Process-driven characteristics are factors that can be 
managed based upon the decisions and specific steps required to develop a trial.  Clinical 
trial-derived attributes are those factors related to the science, statistical, and/or disease of 
the trial and cannot be changed without impacting the clinical trial design. Clinical 
researchers can have a better understanding regarding how long a study will require to 
develop.  Findings from this research provide additional evidence that the characteristics 
that influence the development of Phase III trials are unique compared to non-phase III 
trials.  In addition, the research finds that the greatest impact to development time is 
related to process-driven characteristics, particularly the number of scientific reviews, 
which can be addressed through quality and process improvements.  Coordination 
between those conducting the scientific review and those responding to the review may 
be able to reduce the number of reviews and thus decrease the development time 
required.  
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5.4   LIMITATIONS AND FUTURE STUDIES TO ADDRESS LIMITATIONS 
5.4.1 Research Setting 
The results and findings from this research are only applicable within the context 
of oncology clinical trials, and specifically within the NCI-CTEP research setting.  
Oncology clinical trials can be conducted via multiple sponsors, including industry 
sponsored and at the local institutional level, i.e., a cancer center.  Each of these sponsors 
require unique development processes, organizational structures, and clinical trial 
requirements.  The uniqueness of each institution, including expertise brought forth by 
the clinical researchers and core competence of the institution, may result in different 
results if the research presented in this dissertation is replicated within the individual 
context.  For example, an academic medical center may have a network of rural and 
affiliate institutions to participate on clinical trials in order to increase accrual rates and 
broaden participation on clinical trials.
3
 Having this unique feature within the 
organization may allow for faster accrual rates and therefore early indicators during the 
accrual period of eventual accrual success, as presented in this research, may require 
modification.   
Compared to other diseases, oncology clinical trials are the most prevalent type of 
trials.
4, 5
 However, it is unknown whether clinical trials of other diseases also encounter 
similar barriers to development and accrual success compared to oncology clinical trials.  
Specific interest for further studies may be clinical trials that focus on cardiology diseases 
with it being the leading cause of deaths per year and highest incidence rate in the United 
States.
6
 With fewer clinical trials compared to oncology and a high incidence rate, 
cardiology clinical trials may have different factors related to development time and 
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accrual.  Interest in other diseases with less visibility and incidence rates compared to 
oncology such as sickle cell trials are also pertinent as the characteristics of the disease 
and organizational structure supporting clinical trials may result in different findings 
from this research. 
5.4.2 Uncovering Additional Factors 
Continued research to discover pre-activation factors is essential. The efforts 
summarized in the three primary chapters of this dissertation mainly focus on factors that 
influence timing data with respect to accrual.  
The research presented in this dissertation has only begun the task of 
systematically uncovering the characteristic of clinical trial development time with the 
provided retrospective data. Identification of additional factors that may impact long 
development time would be beneficial in explaining a greater proportion of the variance 
in development time.  It is expected, but not tested, that a large portion of the 
development time variance may be explained by subjective factors that can only be 
evaluated via prospective data collection through surveys and interviews.  With the 
finding that an increased number of reviews result in increase development time, it would 
be interesting to track the miscommunication of comments of the reviewers (also known 
as stipulations) by the principal investigator and research associates developing the 
protocol.  Perhaps the increased number of reviews is attributed to the inability to 
properly address the reviewers’ comments either through vagueness of the comments or 
through misunderstandings of what is a required response to the reviews.   
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The research provides a foundation to begin addressing concerns for portfolio 
management of clinical trials.  Decisions related to the management of a portfolio of 
clinical trials must be derived from a tradeoff between feasibility/operability as well as 
strategic importance.
7, 8
 The research uncovers that development time is a vital measure 
to consider when supporting clinical trial portfolio decisions with regard to feasibility and 
operability.  Furthermore, early indicators of accrual success can be measured of clinical 
trials as early as first patient enrollment.  Typically, there is a pipeline of clinical trials 
within the various stages of development and execution. Clinical trials continually enter 
the system for development, opened to enrollment, and closed to accruals, continually 
monitoring clinical trials across a rolling-time-horizon is important.  Several metrics have 
been identified; however the next step is to apply it to a decision model for the portfolio.   
 
5.4.3 Clinical Trial Success 
The measure of success utilized throughout this research was accrual performance 
of the clinical trial.  It is important to acknowledge that a clinical trial achieving the 
minimum accrual goal is a very minimal measure of trial success.  Additional measures 
of success of a clinical trial are also essential.  One measure of success worth noting is 
that of the measure of publication and scientific importance of the outcomes of the 
clinical trial.  With less than one in five clinical trials result in publication in a peer-
reviewed journal, measuring clinical trials by the quality of the scientific findings are just 
as important as achieving accrual success.
9
    
Future research to address these limitations should be continued by investigating 
what additional barriers to clinical trials are present with regard to factors beyond 
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development time.  Barriers that obstruct the implementation of quality and scientific 
relevance into the study design may uncover additional factors that have been often 
overlooked.   
5.5   FINAL CONCLUSIONS 
5.5.1 For Researchers Investigating Clinical Trial Barriers to Success 
This research delves into the critical intersection between management research 
and health care, specifically in the setting of oncology clinical trial operations.  The 
research bridges the gap between clinical trial development efforts and clinical trial 
effectiveness.  Efforts to reduce the development time therefore not only improve how 
quickly a trial can begin to enroll patients, but it also improves the likelihood of 
achieving accrual success.  This research also provides indicators during the early accrual 
performance that can be used to predict accrual success, and it identifies clinical trial 
characteristics that are correlated to long development time. 
Findings from this research impact future research related to the investigating 
clinical trial barriers by providing new opportunities to improve clinical and translational 
science effectiveness.  With little research focused on pre-activation activities and early 
accrual performance of clinical trials; this research emphasis the importance of such 
research 
Focusing on the issues regarding clinical trial operational effectiveness also 
creates opportunities to apply operations and management (OM) theories to investigate 
relevancy of past research towards a new research settings.  Potential application of OM 
theory to the design and development of clinical trials is outlined with a focus of supply 
 102 
chain management as well as a summary table for supply chain management, job shop 
scheduling, and new product development.
10
 Continued efforts in this research may help 
established the applicability of current management theories to the health care setting or 
it may highlight the uniqueness of health care compared to other industries. 
5.5.2 For Clinical Trials Offices and Others Developing and Managing Oncology 
Clinical Trials  
From the perspective of those involved with the implementation of oncology 
trials, this research highlights the importance of both the development process as well as 
the early accrual period.  Specifically, evidence has shown that greater development time 
has an adverse impact on accrual success.  Unnecessary delays during the development of 
a clinical trial should be avoided and decisions to “tinker” or revise the clinical trial 
causing additional delays should be made with the consideration of the potential tradeoff 
in likelihood of achieving success.
11
 For example, financial and contract negotiations 
have become integrally tied into the design and development of a clinical trial and can 
often cause delays due to the administrative barriers of synchronicity.
3
 This research 
suggests that it is in the best interest of both the clinical researcher as well as the sponsor 
to have a clinical trial developed quickly and safely to improve the overall likelihood of 
achieving accrual success; without achieving the necessary accruals, all efforts related to 
failed clinical trials becomes non-value added.  Yet, when negotiating contracts and 
financial agreements, both parties may only look out for the self-interest of the individual 
party thus building in potential delays into the entire process.
10
 Careful consideration of 
the design and development decisions of a clinical trial must be made with regard to both 
the potential consequential delays and the impacts to the overall success of a trial. 
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From the managerial perspective for those who oversee oncology clinical trials, 
this research provides a foundation for identifying specific metrics by which to evaluate 
clinical trials in both the development stage as well as through the accrual stage.  
Identifying the metrics of development time, time-to-first enrollment, expected accrual 
performance, and process-related characteristics allows for the evaluation of all clinical 
trials across a standard set of criteria.  This research address several metrics that can be 
used to determine the likelihood of achieving accrual success as well as predicting the 
expected period to which a clinical trial can complete the development time.  These two 
pieces provide the initial components of both clinical trial performance and scheduling 
required to establish the ability to manage a portfolio of trials.  Managers can utilize the 
findings from this research and couple it with the implementation of overall strategy 
which the organization (specifically NCI-CTEP) follows, in order to improve overall 
clinical trial effectiveness.  
5.6   OVERARCHING CONCLUSIONS  
The research of this dissertation is just the beginning of a growing area of interest 
to improve the operational and scientific effectiveness of clinical research. There are a 
host of other perspectives and academic disciplines that can be applied towards 
improving clinical trial effectiveness; this research embraces the management approach 
and applied it to issues of clinical trial development and operations.  All interdisciplinary 
research efforts and application of research must continue with the utmost intention to 
achieve the ultimate goal of improving standard treatment options and standards of 
oncology practices benefiting the current and future populations afflicted with cancer. 
 104 
5.7  REFERENCES 
1. Lara Jr PN, Higdon R, Lim N, et al. Prospective Evaluation of Cancer Clinical 
Trial Accrual Patterns: Identifying Potential Barriers to Enrollment. Journal of Clinical 
Oncology 2001;19:1728. 
2. Community Clinical Oncology Program (CCOP. National Cancer Institute. 
(Accessed October 31 2008, at http://prevention.cancer.gov/programs-
resources/programs/ccop.) 
3. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, 
infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 
2006;24:4545-52. 
4. Cardiology studies on the decline:  Cancer the most Studied Disease. Clinical 
Cardiology, 2008. (Accessed October 20, 2008, at 
http://www.theheart.org/article/898483.do.) 
5. Karlberg JP. Trends in disease focus of drug development. Nat Rev Drug Discov 
2008;7:639-40. 
6. Deaths-Leading Causes. 2008. (Accessed at 
http://www.cdc.gov/nchs/FASTATS/lcod.htm,.) 
7. Linton JD, Walsh ST, Morabito J. Analysis, ranking and selection of R & D 
projects in a portfolio. R and D Management 2002;32:139-48. 
8. Cooper RG, Edgett SJ, Kleinschmidt EJ. Portfolio management: fundamental to 
new product success. The PDMA Toolbook for New Product Development, John Wiley 
& Sons, Inc, New York 2002:331-64. 
9. Ramsey S, Scoggins J. Commentary: practicing on the tip of an information 
iceberg? Evidence of underpublication of registered clinical trials in oncology. 
Oncologist 2008;13:925-9. 
10. Cheng SK, Dilts DM, Ferranti LB. Uncovering the Administrative Barriers in 
Healthcare:  The Application of Supply Chain Management Techniques in the 
Development of Clinical Trials. In; 2008. 
11. Dilts DM, Sander AB, Cheng SK, et al. The Steps and Time to Process Clinical 
Trials at the Cancer Therapy Evaluation Program. J Clin Oncol 2008. 
 
 
 
 105 
CHAPTER VI 
 
EPILOGUE:  APPLICATION OF MANAGEMENT THEORIES TO A 
HEALTHCARE SETTING 
The past four years of investigating the clinical trial development process through 
multiple settings including four comprehensive cancer centers, three cooperative groups, 
and two government institutions has presented numerous examples and informal case 
studies on the application of healthcare towards management theories.  The combination 
of countless interviews, collecting data from multiple perspectives, and documenting the 
processes required to develop a clinical trial have provided sufficient insight on how 
different participants and organization interact amongst each other.  Three specific 
theoretical management lens of interest of how the development of a clinical trial is 
applicable include supply chain management, new product development and job shop 
scheduling.   
To ignite the extension of management theory into the healthcare setting, research 
has begun to provide the foundation for future research on the theoretical level.  The 
application of supply chain management to the development of clinical trials is presented 
in a formal article.  Additional references that relate to new product development and job 
shop scheduling are presented in appendix A.  Research findings are presented in the 
framework of administrative barriers denoted by structural, infrastructural, and 
procedural barriers.
1, 2
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6.1  ABSTRACT 
The knowledge-based healthcare supply chain is plagued with the same dilemmas 
as those found in the manufacturing environment, hence theories and principles from 
operations management (OM), particularly those involved with supply chain 
management, may be able to be applied to improve overall healthcare system 
performance. The objective of this paper is to show how one aspect of the healthcare 
supply chain, that of pharmacological clinical trials, has a distinct need for the ideas and 
solutions that operations management can bring. Decision science techniques have been 
successfully applied in a variety of industries, yet little of this knowledge has been 
translated onto the decision processes required to design and activate drug clinical trials 
(Dilts & Sandler, 2006; Dilts, Sandler, Baker, Cheng, George, Karas, McGuire, Menon, 
Reusch, Sawyer, Scoggins, Wu, Zhou, & Schilsky, 2006). Using process and timing data 
collected from multiple sites concerning oncology clinical trials, we show that there is a 
wealth of opportunities to apply OM knowledge in healthcare.  
6.2  INTRODUCTION 
Total national healthcare expenditures within the U.S. rose 7.9% or 16% of the 
gross domestic product (GDP) in 2004, and are projected to reach 20% of the GDP in the 
next decade. This $1.9 trillion is 4.3 times the amount spent on national defense 
(Henry_J_Kaiser_Family_Foundation, 2007; National_Coalition_on_Healthcare, 2007). 
As research has noted, this explosive rise of healthcare spending and highest per capita 
spending of any country, does not necessarily translate to achieving better outcomes than 
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other countries who spend considerably fewer resources per capita on 
healthcare(Henry_J_Kaiser_Family_Foundation, 2007).  
One particular healthcare sector, the pharmaceutical industry, continues to 
increase its expenditures in research and development at an even more alarming rate. This 
industry’s top ten companies alone increased their research and development spending to  
$54 billion, with clinical trials accounting for more than 40% of the total research and 
development spending (Clinical_Trials_Today, 2007),  this increase  is more than an 
147% increase from 1993 to 2003 (Medical_News_Today, 2006). Clinical trials are a 
critical step in the verification and validation of potential new therapeutics (drugs) prior 
to approval by the Food and Drug Administration (FDA).  
Interestingly, while the development time for other new-to-the-world products 
have decreased from 41.7 months to 24 months from 1995 to 2004 (a decrease of 42%) 
(Adams & Boike, 2004; Slater, 2005), the time to develop a new drug has increased from 
56.4 to 144 months (increase of 155%)(Slater, 2005) in the same time frame. And along 
with this increase in time is escalating costs. With cost reaching over $800 million per 
drug, pharmaceutical firms must rely on external partners, suppliers, and government 
agencies to aid in new product development (DiMasi, Hansen, & Grabowski, 2003; 
Adams & Brantner, 2006). With such a large investment reaping disappointing results as 
nine of ten drugs fail to successfully enter the market (Clinical_Trials_Today, 2007), the 
time has come to study whether decision–making techniques utilized in other industries 
can be applied to the healthcare industry to 1) improve outcomes and 2) reduce 
operational barriers.  
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Pharmaceutical firms do not work alone in the development and testing of novel 
drug therapies and indications. Compared to other industries, the pharmaceutical supply 
chain is highly disbursed across different levels of intermediaries, which includes 
healthcare professionals, government employees, research scientists, and hospital 
systems. However, considering the time and cost to develop a new treatment option, 
increasingly pharmaceutical firms are turning to their supply chain to aid them in 
developing new product. This is similar to what is occurring in manufacturing, where 
suppliers are becoming co-product developers (Handfield, Ragatz, Petersen, & Monczka, 
1999).  One key aspect of drug development is that of testing on human subjects, which is 
known as a clinical trial.  
The clinical trials process is a long and arduous one that requires multiple 
individuals, in multiple institutions and with multiple job descriptions to interact to 
complete the initial tasks to test a drug or treatment. Development of a trial can require 
both internal coordination as well as external coordination with government agencies, 
such as the National Cancer Institute (NCI), a division of the National Institutes of Health 
(NIH).  The NIH is the “primary federal agency for conducting and supporting medical 
research” (National_Institutes_of_Health, 2007), which includes clinical trials. As supply 
chain integration requires external and internal cooperation, the healthcare supply chain 
should be able to translate existing research into its unique needs.  The need for such 
translation can easily be seen as research at one typical comprehensive cancer center 
showed that 55% of all studies that were opened for patient accrual resulted in such a low 
number of patients (<5) that the no statistically valid conclusions could be drawn from 
the trials. With months or years involved in the setup of a clinical trial, the clinical trials 
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process has significant room for improvement and it has been suggested that decreasing 
the times to conduct clinical trials will directly result in an overall decrease in the cost of 
treatments at the patient’s bedside (DiMasi et al., 2003).   
There are three types, or phases, of clinical trials (I, II, and III). From an initial 
limited number of patients, or accruals, required the number of accruals increase by 
phase. Each clinical trial phase can be divided into two aspects: 1) development of the 
clinical trial or testing protocol and 2) execution the trial and evaluation the results. 
Interestingly, while there is a great deal of literature in the medical domain about the 
second aspect, there is virtually none concerning the first. This is similar to the state of 
manufacturing knowledge pre-1970’s: there were volumes of research on manufacturing 
execution but a dearth on setup reduction. Our paper demonstrates how OM 
manufacturing and service literature on setup can be used to address very similar issues in 
new drug development.  
There have been numerous studies that have focused on reducing the time to 
execute a clinical trial, such as increasing accruals and improving communication of the 
announcement of studies (Comis, Miller, Aldige, Krebs, & Stoval, 2003; Corrie, Shaw, & 
Harris, 2003).  While such investigations have lead to improvements of the operation of 
individual clinical trials, Dilts et al. (2006a,b) found that the potential of reducing time to 
completion and potential cost savings are found not only in the process of conducting a 
clinical trial, but also in the setup and development of the clinical trial.  In one case, the 
mean time of  clinical trial development at a oncology clinical trial cooperative group 
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(CTCG)
1
 is 2.1 years; which is approximately half of the total time to complete the 
clinical trial (Dilts et al., 2006; Keyhani, Diener-West, & Powe, 2006). It is logical to 
assume that this set-up time is affected by some of the same causes as found in other 
service and manufacturing organizations.    
Supply chain management knowledge has evolved greatly in the past four decades 
and has been the focus of numerous articles (Croom, Romano, & Giannakis, 2000; 
Gunasekaran, 2005) and books {Simchi-Levi, 2000 #6} in recent years. A supply chain is 
a collection of firms who, while maintaining local autonomy and decision-making 
capability, act jointly to fulfill customer requirements {Simchi-Levi, 2000 #6}.Yet the 
application of theory into practice of the healthcare supply chain is sparse.  
Few have studied the components of operations management combined with 
decision science in this unique setting and there are great strides that could be made by 
sharing knowledge.  For example, Tucker (2003) examined the impact of operational 
failures on hospital nurses and patients and found that failures occur with such regularity 
that they are “deemed inevitable”. Her study notes that most operational failures are from 
breakdowns across organizational boundaries and that those most affected learn to 
compensate quickly for those failures, which may result in more organizational 
disconnects as the problem root cause is never discovered. Organizational behavior 
literature shows that organizational learning across systems is difficult, and it is nearly 
impossible when systemic problems are compensated for at difficult junctures by 
                                                
1
 A group of researchers, cancer centers, and community doctors who are involved in studies of new cancer 
treatment, prevention, early detection, quality of life, and rehabilitation. Clinical trials carried out by 
cooperative groups are sponsored by NCI, and large numbers of patients take part in many locations. 
(www.cancer.gov) 
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different players, without the others knowledge of 1) a problem or 2) their decision’s 
unintended consequences on other parts of the organization (Chinander & Schweitzer, 
2003). As we will show, such problems are rampant in the clinical trial setting, much as it 
was in Tucker’s hospital patient care setting.  
6.3  STUDY SETTINGS 
Healthcare is facing many of the challenges previously confronted by 
manufacturing.  If one compares the development of semiconductor processes, chemical 
manufacturing processes, or any other generic manufacturing process, to that of the drug 
development process, one can easily see the similarities. While drugs are not being 
“assembled” per se, the processes required to “build” a successful drug, from laboratory 
to market, are analogous to those one would find in a classic job shop, new product 
development or supply chain management situation. 
Rather than investigate all possible clinical trial types, we will focus on oncology 
clinical trials as a representative example. Cancer, one of the primary causes of death in 
America, has had a revolution in the number and types of drugs under development. 
From targeting cancerous cells directly, therapy has branched into targeting the “food 
supply”, i.e., the blood supply to such cells. This has required the clinical evaluation of a 
host of additional therapeutics. Within the cancer clinical trials setting, the trials can be 
classified according to their purpose and development phase. For example, there are six 
primary types of clinical trials: 1) prevention trials, 2) screening trials, 3) diagnostic 
trials, 4) treatment trials, 5) quality of life  trials, and 6) genetic studies; and four primary 
phases of human clinical trials: phases I, II, III and post market phase IV (NCI, 2003). 
 112 
Our research setting focuses on the process of the largest and most complex types of 
clinical trials, that of phase III treatment clinical trials. “These (treatment) trials test many 
types of treatments, such as new drugs, vaccines, new approaches to surgery or radiation 
therapy, or new combinations of treatments (NCI, 2003)”. Phase III studies typically 
require more time and resources as well as patients.  
Clinical Trials are conducted for many diseases and diagnoses in numerous 
organizational structures, including both private and government settings. We limit our 
research study population to cancer clinical trials in two specific government funded 
settings within the National Institutes of Health (NIH)’s National Cancer Institute (NCI): 
cooperative oncology groups and comprehensive cancer centers. There are two reasons 
for this choice. First, most Phase III clinical trials are government sponsored to a certain 
extent, so the two sites can be considered representative of oncology clinical trials sites. 
Second, phase III trials are the most complex, hence they will better show the potential 
areas of application of OM techniques in the healthcare supply chain. Because the 
infrastructure of the oncology clinical trial development is intricate and overlapping, we 
begin by discussing each of the major partners in the supply chain.  
6.3.1  Supply Chain Partners: NIH, NCI, CTEP, CTCGs, CCCs, and 
 Pharmaceutical/ Biotechnology Firms  
The National Institutes of Health (NIH) is one of eight divisions in the Public 
Health Services, which is part of the Department of Health and Human Services of the 
Federal government (National_Institutes_of_Health, 2007). Their mission is to foster and 
provide medical and behavioral research to the nation.  Currently, the NIH invests nearly 
$30 billion per year in medical research in the United States. While most of the institutes 
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and centers budget appropriations are scheduled to increase, one institution, the National 
Cancer Institute (NCI) projected 2008 budget is projected to decrease $9 million 
(National_Institutes_of_Health, 2007).  
The NCI is the federal government’s program responsible for conducting and 
supporting cancer research and training. Its vision is to have “a nation free from the 
suffering and death due to cancer by 2015 with dramatic reductions in cancer 
incidence”(NCI). Supporting more than 1300 clinical trials a year and aiding more than 
200,000 patients, the NCI is organized is pervasive throughout the nation. With this 
amount research being conducted, it is important that coordination takes place and this is 
one of the primary mandates of the Cancer Therapy Evaluation Program (CTEP), which 
attempts to forge broad collaborations within the research community and works 
extensively with the pharmaceutical/biotechnology industry to effectively develop new 
cancer treatments (CTEP, 2006).   
Although various groups and organizations, both for-profit as well as non-profit, 
may develop and sponsor clinical trials, two key groups who conduct clinical trials are: 1) 
Clinical Trials Cooperative Groups (CTCGs) and 2) Comprehensive Cancer Centers 
(CCCs), both sponsored by the NCI. Clinical Trials Cooperative Groups include 
researchers, cancer centers, and community physicians throughout the United States, 
Canada and Europe. CTCGs involve more than 1,700 institutions, enrolling more than 
22,000 new patients each year (National_Cancer_Institute, 2007) This consortia of 
members allows CTCGs group studies to reach a larger patient population to enroll in 
cancer treatment clinical trials and they have been pivotal in completing Phase III trials 
(Comis, 1998). 
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The NCI also sponsors clinical research through approximately 60 cancer research 
institutions and 39 Comprehensive Cancer Centers (CCCs) located across the United 
States (NCI, 2006). Comprehensive Cancer Centers are those organizations that have 
proven to successfully initiate and conduct innovative trials and participate in CTCG 
trials.  Selection as a NCI-designated comprehensive cancer center requires rigorous 
qualifications with the center integrating basic laboratory research, clinical research and 
public prevention and they are known as the elite of their specialties. In addition to the 
NCI-sponsored studies, CCCs also support and conduct clinical trials internally initiated 
by their own physician researchers and those sponsored by the 
pharmaceutical/biotechnology industries. All NCI funded studies at CCCs as well as at 
the CTCG group level must be approved through Cancer Therapy Evaluation Program 
(CTEP).   
In addition to governmental support, pharmaceutical and biotechnology firms also 
conduct a significant number of oncology clinical trials, and the pace is increasing. For 
example, more than 100 claims approved for oncology treatment indications in 1990s far 
exceeded the total of those granted in the proceeding 40 years and the growth rate in 
FDA-approved investigational new drug studies for all phases has increased from 3,900 
in 2001 to 4,500 in 2003 (Rothenberg, Carbone, & Johnson, 2003). 
With such rapid growth and a wide variety of groups and organizations involved 
in oncology research, there is a wealth of potential applications for OM research 
application. We initially selected a comprehensive cancer center for the focus for data 
collection. However, additional funding allowed us to expand our data collection to 
include one major clinical trial cooperative group. While the results discussed in the 
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article are only for those two sites, we have also studied two additional CCCs and one 
additional CTCG. Those results are consistent with the data presented here. 
6.3.2  The Clinical Trial Cooperative Group and the Comprehensive Cancer 
Center 
The studied CTCG is a national clinical research group with its central office in 
the Midwest and its Statistical Center in the South. Since its founding, it has grown into a 
national network of nearly 30 university medical centers, over 200 community hospitals, 
and over 3,000 oncology specialists. It has been among the leaders in designing studies 
specifically for the elderly, studies that concern quality of life in cancer patients, and in 
introducing novel therapies and treatment approaches for patients with poor prognoses. 
The investigated comprehensive cancer center is the only one in its state and is 
consistently recognized among the nation’s leading centers for excellence in 
compassionate, individualized cancer treatment. It has nearly 300 investigators in seven 
research programs, with more than $150 million in annual research funding. There are on 
average 200 clinical trials ongoing or open to accrual at any given time. Finally, it is 
among the top ten in competitively awarded NCI grant support.  
6.4  DATA COLLECTION 
All clinical trials conducted between the years 2002 and 2005 inclusive were 
reviewed at both the clinical trial cooperative group and the comprehensive cancer center. 
Following Yin’s (2003) case study methodology principles, an interdisciplinary team of 
experts from schools of medicine, engineering and management collected data from 
multiple sources through: 1) extensive staff personnel interviews, 2) analysis of existing 
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process documentation and records, 3) archival analysis of clinical trial initiation data, 
and 4) electronic mail and database records.  Personal interviews permitted questions 
targeting the research objectives of identifying processes and barriers to the opening of 
clinical trials. Objective data collection for the identified sources were chosen because a) 
such documentation was broad and permitted multiple time frames, settings and events, 
and b) archival records are precise, quantitative and have less reporting and selectivity 
biases than documentation (Yin, 2003). One of the interesting findings we discovered in 
such a triangulation methodology was that there were inconsistencies between what was 
said was being done in the interviews, what the policies and procedures documentation 
said should be done, and what the clinical trial record review showed was actually done. 
Use of this three part methodology, implemented at both the CTCG and the CCC, 
resulted in capturing a complete understanding of the development of the process 
structure of the two organizations, and documenting an accurate reflective process map 
and data timing analysis. This research had two primary outcomes:  a) process mapping 
and b) timing analysis. 
6.4.1  Process Mapping 
The first part of data collection was to identify and map existing process steps 
required to open an oncology clinical trial at both study settings.  The conversion of the 
organizational tacit knowledge into a graphical representation resulted in the process 
map, that is, a graphical representation of the flow of inputs, resources, steps and 
processes required to create an output, and in this case to activate a study (Harrington, 
1991).  These data were collected by means of more than 30 initial onsite personnel 
interviews, additional follow-up e-mail correspondence, and a series of at least two 
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clarification teleconferences, with members of the cooperative group and the 
comprehensive cancer center. At least two additional onsite clarification interview 
sessions were conducted at each site prior to the final results presentation. It is important 
to note that the data from the two research sites were collected separately and remained 
confidential.   
6.4.2  Timing Analysis 
Once the process map was complete and verified as accurate, the calendar time 
needed for each of the major process steps required to activate a study was collected.  
These archival data were compiled by scanning more than four hundred historical e-mail 
correspondences per study, 15 file reviews, and a database of 268 clinical trial records.  
By conducting both the process and the timing of each process, the understanding of the 
yield variation will allow effective strategies for process and productivity improvements 
(Bohn, 1995; Sinha & Field, 2005). 
Study selection criteria for detailed analysis included all Phase I, II, and III 
studies opened and completed within the last five years. Within the Comprehensive 
Cancer Center study section, clinical trial selection for this study included not only those 
studies, which originated in a cooperative group, but also, industry sponsored trials, as 
well as those trials initiated at the comprehensive cancer center by their clinical 
investigators. 
There were multiple cross checks of steps and timing at different organization 
hierarchy levels. The interviews were conducted in both individual and group settings 
with the input remaining anonymous. The interview process included both open-ended 
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and close- ended questions. Upon completion, the interviewees were requested to clarify 
specific acronyms, decision point names, position titles and responsibilities. Objective 
data stored in databases or e-mails were crosschecked wherever possible with other, 
independent records. 
6.5  RESULTS 
6.5.1  Initial Observations 
The clinical trials development process is different for the CTCG and the CCC, 
although they both have five main categories of processes.  For the cooperative group, the 
five primary steps are:  (1) initial concept development and approval, (2) protocol 
development, (3) CTEP approval, (4) Centralized Institutional Review board (CIRB) 
review, and (5) study activation (See Figure 6-1).  For the Comprehensive Cancer Center, 
the processes are subdivided into five sections as well:  (1) Initial Preparation (2) 
Approval Process (3) CTEP approval Process, (4) Budgeting and (5) Final Preparation 
(See Figure 6-1).  For studies utilizing federal funds, they are evaluated by CTEP; hence, 
all CTCG studies must pass through CTEP process for concept (initial study idea), 
protocol review, and forms review; only those comprehensive cancer studies funded by 
NCI require CTEP approval.  
Each of these phases for both organizations can be treated as individual tasks in 
the healthcare supply chain.  In this supply chain, there are a greater than 27 different 
types of participants for the CCC and greater than 30 different types of participants for 
the CTCG (See Table 6-1).  The number of processing steps are >110 and >370 for the 
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CCC and CTCG respectively. The number of decision points in the CTCG is >40, and the 
number of places in the process where a trial could loop for rework is nearly 30.  
Because of the host of issues or barriers encountered, we have classified them into 
three categories: 1) procedural (policy differences), 2) structural (process differences), 
and 3) infrastructural (incompatibility of the support structures). Each is defined and 
discussed below.  
Procedural barriers are policies, either formal or informal, that arise from the 
processes required to activate a study and that may inhibit problem-solving actions. For 
example, a procedural barrier occurs when, after a concept is approved by CTCG, the 
concept must then be reviewed by an outside agency (CTEP) before additional work can 
be done on the concept development. Such procedural issues are prevalent and occur 
throughout the development process occurring both internally and at the external 
interface with other supply chain members. 
Structural barriers are created when different participants in the process follow a 
different ordering of steps, which can lead to miscommunication and confusion. An 
example of this barrier is a circular mismatch loop that arises because of multiple 
participants in the process. For example, a pharmaceutical sponsor may require 
information that can only be provided by the CTCG or CCC, who, however, will only 
supply the necessary information after the sponsor agrees to some condition. This can 
lead to a “Catch-22” situation: one group cannot collect the required information until 
they approve a condition, but they will not approve the condition without the information.   
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Infrastructural barriers concern how the underlying system is designed and how it 
supports the interconnection of various aspects of the systems. For example, we 
discovered that there were over seven different numbering systems used to track the 
progress of a clinical trial through a CCC by different functional areas, yet there was no 
master cross listing of identifying numbers.  This is equivalent to a having seven different 
part numbers for the same part, with no mapping among the numbers.  
Integration in the supply chain is important for reducing the amount of each of 
these barriers that are present in the clinical trial development process.  Both sites studied 
exhibited characteristics of supply chain inefficiencies as identified in past supply chain 
literature.  We will utilize supply chain theories as they apply to the healthcare supply 
chain and identify potential opportunities to improve the overall performance throughout 
the system. 
6.5.2  Issues in Health Care Supply Chain Management 
Before turning to supply chain issues in our research settings, we will briefly 
review applicable supply chain research. Supply chain management centers around the 
integrative coordination of material and information flow among various organizations 
involved with the process of producing a specific good or service {Chopra, 2003 #82; 
Simchi-Levi, 2000 #81}. Successful supply chain management requires the integration of 
processes from sourcing, to manufacturing, and to distribution across the entire chain 
(Maloni & Benton, 2000; Cooper, Edgett, & Kleinschmidt, 2001; Chopra & Meindl, 
2003).  Supply chains have become increasing complex as products and services expand 
in complexity to meet ever-higher customer expectations (Berry & Parasuram, 1991).  
Strategies for coordination across functions and across organizations have typically 
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assumed that some kind of centralization power is required in order to retain control of 
the chain (Maloni & Benton, 2000). Such supply chains tended to create oligopolistic 
environments, which relied on authoritative power in order to distribute of 
responsibilities across the suppliers (Maloni & Benton, 2000).   
In the healthcare supply chain, because power is distributed across multiple 
participants, coordination and integration issues are significantly more problematic.  
While the overall process of developing a clinical trial utilize a similar set of processes, 
the participants in the supply chain are decentralized, locally autonomous, and they may 
be under different loci of control.  Such fragmentation as well as the decentralization of 
decision-making makes it difficult for any single organization to dominate the actions of 
others(Burns, 2002).   In clinical trials developed through the CTCG or the CCC, the 
supply chain is composed of various organizations including, but not limited to the 
industrial sponsor, the NCI, and the FDA.  Each these organizations have similar but 
different objectives and requirements when developing a clinical trial.  Additionally, each 
organization is composed of semi-autonomous internal groups.  Specifically in the 
comprehensive cancer centers, the organization itself may fall under the umbrella of a 
cancer hospital, a general hospital or a major academic medial center, thus, the manager 
of the clinical trial supply chain must interface with various groups or departments, such 
as the Scientific Review Committee (SRC), Institutional Review Board (IRB), office of 
technology licensing, budgeting, and contracts & grants management.  While none of 
these participants are solely dependent upon another for survival, the rapid development 
and successful completion of a clinical trial is crucial to the mission of each of 
committees or groups.   
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6.5.3  Change Management:  Procedural Barriers In The CTCG Supply Chain 
Changing customer demands and market conditions cause downstream 
disruptions in the supply chain, which results in an undesirable consequence to upstream 
suppliers (Magretta, 1998; Johansen, Comstock, & Winroth, 2005).  This often-observed 
bullwhip effect occurs when the demand distortion causes large variations and propagates 
in an amplified form throughout the entire supply chain (Lee & Yano, 1988).  Improving 
communication and coordination among all the participants of the supply chain has been 
suggested in order to avoid supply chain disruptions from this effect.  Changes in 
customer demands and requirements can also result in design changes or rework (Love, 
Li, & Mandal, 1999).  The additional rework has undesirable efforts in terms of total 
project costs, schedule delays, and quality of the product {Davis, 1989 #79}.  In some 
instances, changes to the original design of a product results in the complexities 
outweighing the opportunities to maximize improvements (Mandal, Sinha, & Wright, 
1997). Such changing demands and requirements can result in a procedural barrier in a 
supply chain where there is a conflict in decision- making between producing products on 
schedule to satisfy demand and the decision to change the product or service in the 
supply chain to meet new customer requirements (Naylor, Naim, & Berry, 1999).  
In the clinical trial supply chain, there is a constant temptation to continually 
change the trial to meet the specific needs or condition for the various stakeholders.  One 
primary stakeholder in the clinical trial supply chain is the principle investigator (PI), i.e., 
the researcher who initiates the study concept.  However, while the PI may initiate the 
study concept, changes to the idea by any of the other stakeholders can occur at nearly 
any point of the clinical trial development supply chain.  
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One specific decision-based procedural barrier that plagues the clinical trial 
development process is the impact of the inclusion of modestly value-added 
modifications to the protocol.  Such modifications, through the act of “tinkering”, are 
defined as those changes that do not directly affect the safety of the patients on the study 
or significantly increase its scientific merit.  For example, the addition of correlative 
studies, which focus on answering a secondary research questions but conducted in 
conjunction with the primary clinical trial, are often requested during the late stages of 
the development process. This creates additional barriers to the timely opening of the 
study, as the entire protocol may need to be re-reviewed by all stakeholders.  While the 
inclusion of additional correlative studies may prove to be beneficial to the overall 
scientific body of knowledge, the delay in opening the primary clinical trial can diminish 
its overall performance as well as prohibit potential patients from benefiting from the 
most recent treatment options.  It has also been estimated that are major financial 
implications where every day there is a delay to market the costs to the pharmaceutical 
manufacture averages $1.3M (Bodenheimer, 2000).  Such tinkering is analogous to 
adding a minor feature to an automobile which is planned to be introduced within the 
next week, where it is estimated that for every day of delay of introducing a new product 
model results in a $1 million loss in profit {Clark, 1989 #81}.  While the addition of 
these features can be of value, adding the new feature during the late stages of the 
development process will cause subsequent delay to market entrance and hence loss in 
potential profit. By allowing such decisions throughout the clinical trial development, the 
supply chain can be continuously disrupted, resulting in overall inefficiencies.   
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6.5.4  Transaction Costs:  Procedural Barriers In The CCC Supply Chain 
Policies outlining the standardization across the supply chain have been used to 
prevent procedural barriers from entering the system.  Standardization allows a common 
shared mechanism to orchestrate transactions (Thompson, 1967).  One acknowledged 
form of standardization is the process of conducting financial exchanges (Domowitz, 
1995; Economides, 1999).  Specifically, in manufacturing, contracts and negotiation rules 
are standardized in order to decrease the overall cost of trade among the different 
suppliers.  Blanket contracts and purchase orders are one method of reducing the amount 
of transaction costs from financial negotiations.  By creating blanket agreements, an 
initial purchase-order goes through an approval process by both parties.  Any subsequent 
orders or agreements are then conducted under the pre-approved purchase-order thereby 
saving time and cost.  Blanket agreements avoid the administrative expense of processing 
multiple agreements while also streamlining transactions between suppliers.   The 
creation of blanket agreements, if initiated properly, allows procedural barriers to be 
reduced and non-essential steps to be removed from the supply chain process. 
Organizations that are involved in the clinical trials development supply chain 
also conduct blanket agreements between the different suppliers, which are referred to as 
master agreements.  While this step is conducted in order to decrease the time required 
for completing various components of the clinical trial, these benefits were not observed 
through the comprehensive cancer center studied.  Procedural barriers were created when 
the different participants of the supply chain did not follow the processes and policies that 
were defined by the master agreement.  For example, it was common for sponsors to 
resubmit different contracts when requesting a clinical trial, ignoring existing master 
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agreement. What this meant is that each contract had to be inspected to verify that it was 
consistent with the master agreement. Hence, any labor or time saving was negated by the 
need to inspect every agreement. This is similar to a manufacturing organization, which 
pre-qualifies vendors for quality but still does a 100% inspection of any part sent by that 
supplier.  
6.5.5  Long-Term Supplier Relationships:  Structural Barriers In The CTCG 
Supply Chain 
Supply chain management has shown the effectiveness of a long-term perspective 
in order to increase the predictability of supply and demand.  For example, it has been 
shown in the US auto industry that the selection of the supplier through cooperative long-
term relationships is a strategic decision that provides a competitive advantage (Choi & 
Hartley, 1996).  Choi and Hartley’s research found the importance of consistency above 
all other factors in supplier selection.  These long-term relationships with suppliers are 
vital throughout the supply chain, but as the dissolving of the Firestone and Ford 
relationship exhibits, the continued cooperation and collaboration is difficult to maintain.  
Often times, conflicts in the supply chain arise among participants that stems from the 
incompatibility and unclear roles between suppliers (Heide, 1994).  Changing objectives 
can dramatically change the supply chain environments (Macneil, 1980; Heide & John, 
1990).  Because dissonance between suppliers is formed when cooperative behaviors are 
diminished, participants in the supply chain may cause structural barriers, such as 
following different ordering of steps or prompting inconsistencies throughout the 
processes.  Structural barriers may also form unknowingly between participants in the 
supply chain because the two systems do not coincide with the needs of the other, for 
example, if the customer relationship management system of the supplier is not 
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compatible with the supply chain management system of the purchaser.  Supply chain 
management literature has shown that reducing the number of suppliers and participants 
in the system, and working more intensively with those remaining suppliers to establish a 
long-term relationship may help avoid or minimize structural barriers in the supply chain 
(Cox, 1999). 
The same principles and observations can also be applied to the healthcare supply 
chain.  Specifically in the development of clinical trials, our results revealed that the time 
to complete the development of the clinical trial was impacted greatly by the specific 
participants involved.  With more than 27 different types of groups or participants 
involved in developing a clinical trial, the number of different combinations of types of 
groups caused high variances in the processes and sequencing in the supply chain.  Each 
type of participant involved in clinical trial development, such as the specific corporate 
sponsor’s lawyer, followed different process steps. Hence, the supply chain must 
continuously adapt its steps according to which participant is involved, and at what 
decision point in the development of the clinical trial they become involved.  Such is the 
case with coordination between a cooperative group and the CTEP.  CTEP has the 
responsibility of reviewing the clinical trial for scientific merit, safety, and feasibility.  
Additionally, as each of the major trial components, such as the protocol is completed, 
CTEP must review the contents and may request modifications or rework, prior to its 
approval.  Structural barriers arise because often a different CTEP reviewer is assigned, 
and not the original reviewer, to evaluate the resubmission of the clinical trial protocol 
addressing the issues identified by original CTEP reviewer. Consequently, reviewer 
preferences and experiences may lead to a conflict in the changes resulting in multiple 
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loops throughout the system. Furthermore, the original suggestions on how to resolve 
specific issues may be lost because of the changing participants.   
6.5.6  Roles In The Clinical Trial Supply Chain: Structural Barriers In The CCC 
The successful defining of roles and relationship among the supply chain 
participants are important to create an effective supply chain.  By having defined 
relationships that integrate the supply chain, redundancy and the overlap of similar 
processes across the supply chain can be avoided (Lassar & Zinn, 1995). Overlapping 
processes often occur when supply chain participants are operating in multiple supply 
networks and such an overlap can lead to scope-creep, where the participant extends 
beyond the boundaries of their mandate. For example, many aeronautical firms are 
involved in producing products for both commercial and defense applications, hence 
product designers may make design decisions in order to capture synergies between the 
two supply chains, even though their mandate is to design parts for one system only. 
Such decisions may make the parts for the commercial aircraft significantly more 
expensive or the parts for the military less likely to achieve desired performance 
specifications. 
Conflicts between the roles and scope-creep have been shown within the clinical 
trial supply chain for CCC studies.  A clinical trial must receive approvals from the 
external agency (FDA) and the internal agency (IRB), prior to opening the study for 
patient accrual.  The FDA has the primary role to ensure internal study validity and 
enable the generation of scientifically relevant results, while the IRB must determine if a 
particular study attains a minimal requirement for ethical conduct of research and patient 
safety.  Conflict in decision approval of the IRB and FDA approval arises due to the 
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inconsistency created between scientific merit and patient safety (Mann, 2002).  Often 
times, these two aspects of the clinical trial are interdependent and require mutual 
coordination between the two agents in the supply chain.  The process of development a 
clinical trial is plagued with seemingly endless loops between multiple disagreeing 
parties, from the smaller departments of regulatory and the principle investigator, to the 
larger review boards such as the IRB and the FDA review.  Towill (1996) suggests that 
supply chain processes can be greatly improved by simplifying the scope of decision-
making of each supplier and eliminating excess procedures, which may create 
miscommunications.  This conflict of the scope of the decision could benefit from the 
better communication between the two agents within the supply chain (Love et al., 1999).   
6.5.7  Coordination Of Process Improvement: Infrastructural Barriers in the 
CTCG Supply Chain 
Supply chain management requires continued process improvement in order to 
keep up with the changing dynamics of the market.  Changes in the environment and the 
need to be more efficient due to limited resources, require an in-depth analysis of the 
underlying design of the supply chain (Beamon, 1998).   Supply chain management has 
long stressed the need for collaboration among all participants in order to better satisfy 
customer demands and requirements (Ellram, 1990; Towill, 1996).One method of 
developing greater knowledge of issues with supply chain performance and interrelated 
interactions of suppliers is to use simulation techniques(Swaminathan, Smith, & Sadeh, 
1998). Such techniques have been used to examine the impact of specific decisions on the 
entire system as well as to examine the performance and effectiveness supply chain 
reengineering (Frank, Drezner, Ryan, & Simchi-Levi, 2000)..  In order to produce 
effective results across the entire supply chain, organizations must not only be efficient 
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internally, but must also maintain seamless processes across the entire supply chain 
(Towill, 1996). Because infrastructural barriers arise when the coordination is 
diminished, the performance of the highly integrated network of participants and 
stakeholders also is reduced.  Improving processes within each individual supply chain 
participant is not sufficient; the interconnects throughout the entire system have been 
found to be critical in order to show overall improvements (Barbuceanu, Gray, & 
Mankovski, 1999).   
For the clinical trial supply chain, we completed simulations on the healthcare 
supply chain. Through simulation depicting a dramatic reduction of processing time 
within the cooperative group, we observed only a decrease of 6.78% in time in the 
development of a clinical trial.   In order to achieve the level of improvements sought, we 
discovered that joint improvements between both the internal processes and external 
organizations were required.  Specifically, when the interfaces between CTEP, CIRB, 
and the Cooperative Group were accounted for there was a significant impact in reducing 
the time to develop a clinical trial: we observed an overall improvement of 39.27% with 
respect to the time required to opening a trial (Working Paper).   
6.5.8  Standardization:  Infrastructural Barriers In The CCC Supply Chain 
Supply chain literature has shown that complications in planning and control of 
production are common across multiple suppliers (Chen, 2002).  Each firm has individual 
information on the progress of the supply chain from a single unifocal perspective.  This 
information can either be shared to gain cooperation of other suppliers or hidden in order 
to gain a strategic advantage (Gavirneni, Kapuscinski, & Tayur, 1999; Lee, So, & Tang, 
2000).  Not surprisingly, supply chains are shown to be most effective when its supply 
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chain participants cooperate (Ellram, 1990).  For example, transaction costs are lower 
among all the participants in the supply chain when there is a policy in place to share full 
information (Cachon & Fisher, 2000).  Included in cooperation is the transparency of 
product tracking so that participants in the supply chain have the ability to predict 
demand (Schary & Skjett-Larsen, 2001). One supply chain example of this is in the 
international flow of cargo, which requires both domestic and multi-national trucking, air 
transportation, and freight forwarding.  It is only through the ability to share information 
using common standards of progress tracking can logistics optimization be conducted and 
transaction costs be reduced throughout the entire chain.   
Interestingly, in oncology clinical trials, there is no such transparency in tracking 
individual trials. Our study of a comprehensive cancer center found that the tracking of a 
single clinical trial was being conducted based upon organizational divisions of each 
component rather than by the entire clinical trial itself.  This resulted in seven different 
identifiers in seven different progress-monitoring databases. As one clinical trial had no 
less than seven different numbers assigned as a reference number for the various groups 
within the process, this lack of standardization could contribute to confusion when one 
department is contacting another department concerning study status as well dictate 
repetitive tasks (Burns, 2002). There is limited visibility into the entire process spanning 
across organizations; therefore the lack of communication when developing an individual 
clinical trial is apparent at many steps. Additionally, misinformed decisions made 
pertaining to the development of the clinical trial were being made because the lack of 
communication and information of other components.   
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6.6 CONCLUSIONS 
Throughout this paper, we have illuminated numerous barriers in the clinical trials 
process and how they are similar or unique to those found in non-healthcare supply 
chains. In this conclusion section, we will concentrate on the implications of our research 
on the two primary study sites: the clinical trial cooperative group and the comprehensive 
cancer center. Additionally, we make recommendations toward how to overcome the 
identified barriers using supply chain theory (see Table 6-2).  
6.6.1 To The Clinical Trial Cooperative Group 
Unlike comprehensive cancer centers where the majority of barriers are internal, 
cooperative groups are challenged with more external barriers as they must satisfy and 
coordinate multiple primary external stakeholders, including governmental agencies 
(NCI, CTEP, CIRB, and FDA), multiple member academic medical centers (AMCs), and 
industry sponsors. External barriers present the additional challenges of lack of control 
and the inability to enforce certain decisions or protocol changes. Each of the above listed 
groups has the power to submit changes to a protocol at any point in time. For example, 
the Cancer Therapy Evaluation Program (CTEP) of the NCI must approve all cooperative 
groups studies. This government-sponsored program has series of checks and balances, 
which include approving an initial concept before the submission of a protocol, approval 
of specific forms to complete for the protocol, and review by the Centralized Institutional 
Review Board (CIRB). Even though a concept has been CTEP approved, the protocol 
often requires multiple iterations between CTEP and the CTCG and this does not 
guarantee that the ensuing protocol will receive approval. Such iterative processes occur 
with each of the supply chain members listed above.  
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Because of all these simultaneous iterations by the various supply chain members, 
it requires more than two years for a study concept to transition thought the development 
phase. During this time, the environment may change, with another drug with similar 
properties receiving a patent or receiving FDA approval. This is similar to the automotive 
industry where a new automotive design can take significantly more to develop a new car 
than the pace of market change. An example of this, is the multiple models of SUVs 
produced in the early years of the 21
st
 century, while the subsequent demand dramatically 
decreased due to the consumer demand for more economy friendly vehicle; resulting in 
billions of dollars in revenue lost by all three of the major U.S. automobile 
manufacturers. Contrast this with Toyota’s performance and its well-known reputation 
for rapid product development and supply chain excellence. What will happen to those 
clinical trials cooperative groups who are unable to timely adapt their supply chain to the 
rapidly changing nature of science and the market?  
Another major barrier faced by CTCGs that they have a highly fragmented group 
of suppliers. For example, most study developers, known as principle investigators, are 
employed at academic medical centers and they volunteer their time to assist in creation 
of the clinical trial. As such, they are both fragmented physically (as they are in different 
geographic locations) and operationally (as they are controlled by different groups). 
Making the process even more difficult to coordinate is that the CTCG headquarters is 
sometimes located in a different location than the regulatory and statistics offices, and 
none of the cooperative groups are located in Bethesda, MD, where CTEP is located. The 
use of virtual co-location, as used by Boeing Rocketdyne, could assist in minimizing 
some of the communication disconnects and fragmentation of decentralization (Burns, 
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2002). In the study, the virtual organizations within Rocketdyne could observe the 
progress and stages of other departments located in another physical area. Similarly, as 
much of protocol writing relies on information from other departments, utilizing a 
computer infrastructure that permits collaborative access to track the protocol’s 
development process could dramatically assist the individual teams in planning and 
completing their portions of the protocol as well as provide a means of accountability for 
timely section completion.  
Another procedural barrier that the CTCG faces is that, due to the voluntary 
nature of their members coupled with their need for government approval, they often 
accept late stage changes after receiving initial CTEP or IRB approval. Examples of this 
include the adding of an additional “arm” or indication for a study or adding a correlative 
study to the original protocols. These late stage additions may require the protocol to 
cycle through the CTEP and IRB approval steps at least one additional time. As literature 
notes “everything that happens to a product (process) as it moves through the (supply) 
chain either adds cost or reduces costs. It either adds value or reduces value” (Burns, 
2002). While these late stage changes may be beneficial, the CTCG should initiate a 
policy requiring that changes are requested in a timely manner, i.e., at the less costly 
early stages of development.   
Unlike comprehensive cancer centers, who may receive financial support from 
multiple areas, CTCGs rely primarily on support from the National Cancer Institute and 
such funding is becoming more difficult to secure, as the National Cancer Institute is one 
of only two sectors of the National Institutes of Health expected to experience a decrease 
in its budget. Similar to the funding decreases experienced by Airbus, CTCGs must show 
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that they are utilizing the funds appropriately and efficiently; sometimes this should mean 
“cutting their losses” on a study and devoting their resources elsewhere, something that 
our data show cooperative groups rarely do. While these financial concerns are abound, 
until recently, the healthcare industry appears to have focused only on the downstream 
supply costs (i.e., direct patient cost), while ignoring the supply chain upstream 
costs(Burns, 2002). This leaves a great deal of room for application of OM techniques to 
overcome the barriers identified in this paper.  
Expanding beyond the view of a clinical trial as part of a supply chain, it is also 
possible to view the clinical trial process as a serial new product development (NPD) 
process. NPD structural and infrastructural barriers are evident with the cooperative 
group’s limited use of modularity design and portfolio management. Within the 
cooperative group setting are disease-based divisions, each of whom individually bases 
its request for protocol approval only on its existing pool of potential projects and it 
disregards the number of overall submissions or other division’s submission requests. 
Each group submits as many proposals as it wishes without an imposed limit or 
prioritization list. By enlisting portfolio management techniques and requiring the disease 
team chairs to submit a prioritization list, the cooperative group can then form a better 
portfolio of the potential protocols within each disease group. This is currently being 
experimented with at the CTCG.  
6.6.2  To The Comprehensive Cancer Centers 
A comprehensive cancer center’s most frequently encountered barrier is the 
multiple departments, itinerations and loops that a concept and protocol must go through 
prior to receiving final approval. As each department, such as regulatory affairs, has its 
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own set of requirements and identification codes, it is difficult in the extreme to track the 
progress of the trial from one department to another. Also, many of the process steps are 
completed in functional silos, and we discovered that many steps are repetitive and filled 
with time- consuming revisions. There is a pool of clinical trials underdevelopment at any 
one time and each major processing group is allowed to set its own priority for selecting a 
study to work on from this pool. This situation is analogous to the automotive 
manufacturer OEM supplying the parts for a truck while the assembly line is being set-up 
for a luxury car, while the marketing department has promised the release of a new 
hybrid. Similarly, in clinical trials development, the regulatory department may have its 
own imposed deadlines for particular studies or practicing firefighting with another 
clinical trial that has been opened but is encountering problems. Simultaneously, the 
contracts and budgets groups may be unaware of the progress (or lack thereof) of the 
regulatory group,  and be vigorously pursuing a different path. Interestingly, both groups 
must come together for Institutional Review Board (IRB) submission, who, in turn, has 
its own unique, stringent requirements, timeline of submissions, and schedule of 
meetings.  
Venturing beyond supply chains, the lessons learned from the job shop literature 
indicate that use of cellular teams may be an alternative to the comprehensive cancer 
centers functional silo set up (Hyer & Wemmerlov, 2002).  The use of cellular teams may 
assist in reducing communication gaps between the involved departments as well as 
reduce the number of iterations required as each group is represented during meetings so 
that the changes to the protocol are made earlier in the process, leaving only minor 
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changes in the late stages of the clinical trial submission.  As is well known, changes 
early in the development process tend to be less costly and less time consuming.  
Comprehensive cancer centers are also faced with the daunting task of completing 
the requirements of opening numerous types of cancer studies by different financial 
sponsors, such as the government, internal institutional support, or pharmaceutical/ 
biotechnology industry.  Surprisingly, the steps and order of the steps are different 
depending upon where the study originates (i.e., government, internal or industry) and, 
because of this, CCC often approach each study as if it were a radical innovation. 
However, our data show that most studies are actually incremental studies based on a 
previous Phase I or II investigation. For example, a prior clinical trial may focus on the 
drug efficacy and safety aspects, but not consider the patient’s quality of life and the new 
proposed study’s goal could be to assess the patient’s quality of life. Another example is 
using an established a clinical treatment for different disease indication, e.g., using 
Bevacizumab for prostate cancer instead of lung cancer. Instead of using previous study 
design knowledge, the investigator and clinical trials department redo all the steps 
required for a new protocol, including such tasks as: determining drug dosage and side 
effects, and developing a completely new protocol template. These steps are redundant 
and consume valuable time in the process, as a “new” protocol requires more checks and 
balances than incremental protocol amendments. 
One opportunity for improvement is the potential for use of modularity in 
protocol design and development.  Because studies can originate from three different 
sources (government, internal or industry) with each having a different approval process, 
the standardization of any steps may shorten the process. For example, the use of the 
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USB interface standard allows for a wide variety of peripherals created by a wide variety 
of manufacturers. The standardization of protocol templates and department submission 
forms would dramatically reduce the amount of with repetitive information required by 
the various stakeholders.  
6.6.3  The Potential for Operations Management Lessons from Clinical Trial 
Development 
The synergies between clinical trials and manufacturing research are not one-
sided.  Lessons and observations from investigation the clinical trials development 
process and the healthcare supply chain can foster additional rigorous research in topics 
of direct interest to operations management researchers.   
One particular instance that was found to be prevalent in our study was that both 
research sites had designed only one internal formal decision point to stop the clinical 
trials development process; although other members of the supply chain could halt its 
development.  This process remained constant even for a study that was known to have 
major flaws and showed signs of failure, thus consuming resources that could have been 
utilized more effectively if devoted to studies that were more promising.  Such 
application could have been applied to the FBI information management system, known 
as the Virtual Case File, a project that was intended to replace outdated technology in the 
wake of 9/11. It was canceled in 2005 at the cost of $104 million after achieving none of 
its original goals. Disturbingly, the project began showing signs of failure as early as 
2003 (Paltrow, 2005).  The decision to terminate the project in earlier stages of 
development could have benefited other projects, including the current project, the 
Sentinel project, which is now underway as a solution to the aforementioned failed 
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project. This failure to terminate in highly diverse settings of clinical trials and FBI IT 
points to a significant underlying operations system problem that deserves further 
investigation.  
As with many development processes, the clinical trials development process has 
a degree of sunk cost bias, which assumes that once a trial idea enters the system it 
should continue development because of the work already spent on its development 
(Kahneman & Tversky, 1979).  This bias, coupled with the internal organizational 
loyalties’ was stated by interviewees as contributing factors to the low cancellation rate. 
However, while these biases may be present, our findings indicate that even without these 
additional influences, the current process does not have the means to stop studies that 
progress passes the one potential stoppage point to another.   
Our research has illustrated that there are supply chain techniques that can be 
applied to improve the clinical trials development process. This theoretical lens provides 
options to overcome the barriers of this lengthy, complex and onerous process. Whether 
addressing the procedural barriers of numerous internal and external loops, or the 
infrastructural barrier of the hazards of inconsistent protocol numbering or performance 
measures, each lesson from the manufacturing literature and industry provides an 
invaluable untapped resource. 
We trust that our research in only the initial foray into the complexity of new drug 
and treatment development. As we have shown in this final section, there are other lenses 
from which to view new drug development process, including perceiving it as a serial 
new product development issue or as a potential application of job shop sequencing and 
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scheduling research. We will be utilizing these additional lenses in order to reduce the 
time from drug development at the bench to the patient bedside. With over 1.4 million 
new cancer diagnoses every year, it is imperative that we apply known solutions to this 
problem in healthcare. 
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FIGURE 6-1: SUPPLY CHAIN NETWORK FOR THE CLINICAL TRIAL COOPERATIVE GROUP AND THE COMPREHENSIVE CANCER 
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TABLE 6-1:  PROCESS AND TIMING DESCRIPTION FOR CLINICAL TRIAL DEVELOPMENT FOR CTCG AND CCC 
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TABLE 6-2:  Application of Supply Chain Management Theories to the Health Care Supply Chain 
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TABLE 6-3: APPLICATION OF MANAGEMENT THEORETICAL LENS TO THE HEALTH CARE SUPPLY CHAIN 
